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Abstract 
Patient Reported Outcome Measures (PROMs) are instruments that seek patients’ views 
on symptoms, functional status and health related quality of life. My thesis analyses 
data from the Stent or Surgery Trial. A cohort of 988 patients completed several PROMs 
before, and at two time points after their revascularisation procedure, and this data 
forms the basis of my thesis.  
I found discordance between patients’ and their physicians with physicians slightly 
overstating angina burden prior to revascularisation and under reporting at 
twelve-months post procedure by comparison to patients.  
I compared the generic EuroQol EQ-5D and disease specific Seattle Angina 
Questionnaire (SAQ) to assess the degree of agreement. I found the EQ-5D visual 
analogue scale (VAS) had poor correlation with any of the five domains of the SAQ. 
However, the VAS relates to how a patient feels at the time of completion and the SAQ 
refers to the previous four weeks.  
I then compared the full 19 question SAQ with a short 7 question version (SAQ-7). A 
single summary score was calculated for both instruments. Each timepoint showed a 
strong positive linear correlation above 0.9. The implication of this finding is there may 
be greater take-up for a PROM with fewer questions and that a single summary score is 
easier to understand.  
Finally, I examined some strengths and weaknesses of questionnaires. Advantages 
include expense, practicality, speed and anonymity. Disadvantages included user 
fatigue, dishonesty and bias in the way the questionnaire is designed. 
PROMs in the UK tend to be used to compare performance between individual 
operators or Trusts. In other countries such as Sweden they are used to calibrate 
individual patients’ treatment plans.  
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 Introduction 
“The ultimate measure by which to judge the quality of a medical effort is whether 
it helps patients (and their families) as they see it. Anything done in healthcare that 
does not help a patient or family is, by definition, waste, whether or not the 
professionals and their associations traditionally hallow it” (1) 
 
For many years the impact of healthcare interventions was measured in terms of 
the ability to limit mortality (2). Mortality data is provided in detail by the Office 
of National Statistics (ONS) via its website at www.ons.gov.uk (3). A statistical 
bulletin in 2013 states that infant mortality decreased, and that cancer was the 
most common broad cause of death accounting for 29% of all deaths registered. 
The bulletin states the number of deaths recorded is related to the size of the 
population and its age distribution.  We can see that 28% of all deaths were due 
to circulatory diseases such as strokes and heart disease. The bulletin also states 
that over the last century there have been steady decreases in mortality rates of 
three main causes of death (cancer, circulatory and respiratory). The bulletin 
went on to say this is partly due to improvements in treatment and diagnosis.  
Several other factors contributed to reductions in mortality. Cutler and Meara (4) 
make the point that all-cause mortality was in decline well before modern 
medical treatment was available. The reductions could be related to nutritional 
improvements and public health measures. In the first part of the 20th century 
there were advances in the treatment of infectious diseases and the introduction 
of penicillin. Cutler and Meara (4)state “The cumulative decline in deaths from 
infectious diseases from 1900 to 1960 was 92%”. They also state the cumulative 
decline in cardiovascular disease mortality between 1960 and 1995 was close to 
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two-thirds. This reduction in cardiovascular mortality could be attributed to 
several factors, including drugs to dissolve blood clots, surgical procedures such 
as bypass surgery, angioplasty, coronary care units, trained response teams and 
pharmaceuticals. Other factors that may contribute to reductions in mortality 
include changes in behaviour such as reduced rates of smoking, socioeconomic 
factors such as better education or increased aspirations for better health (4) 
Education campaigns have influenced people’s diet, lifestyle and smoking habits, 
an example being a campaign called ‘Stoptober’ which encouraged people to 
stop smoking for the month of October(5). However, Devlin and Appleby (2) point 
out that only a small proportion of people being treated in health systems in any 
given period actually die. Most receive some improvement due to their 
treatment. Devlin and Appleby point out that publishing data on reinfections, 
reoperations and adverse events tell us nothing about the patient experience of 
healthcare. One of the most important, yet difficult, questions in clinical research 
is to identify the outcome measures that might best provide insight into the 
impact of the intervention being tested.  
Mortality data is, nevertheless, useful for several reasons. These include 
population estimates, examination of suicide rates or drug related deaths, 
analysis of infant mortality and comparison against the census estimates each 
decade. These epidemiological analyses inform estimates of trends at a 
population level. However, they tell us nothing about the patient experience of 
healthcare.   
P a g e  13 
 
The evaluation of services tended to focus on efficiency of service delivery or the 
range of services on offer (6). These measures - although important - say nothing 
about the patient’s own health. Lord Darzi’s interim report on the future of the 
National Health Service (NHS) in 2007 recommended that patient reported 
outcomes should have a greater role (7). In the NHS Contract for Acute Services in 
April 2008, Patient Reported Outcome Measures (PROMs) were recommended 
for hip and knee  replacements, groin hernia and varicose vein surgery (8). 
An example of the difference in clinical outcomes as opposed to the patient 
experience would be the treatment of prostate cancer. Penson in 2001 (9) stated 
that following nerve-sparing radical prostratectomy the rate of impotence varies 
between 32% to 70%.  Clinically, following surgery there will be an increase in 
five-year survival but at the cost of loss of sexual function and erectile 
dysfunction (ED). Penson’s report was a broad review of several health related 
QoL instruments used in ED and pointed out that function is generally assessed 
but ‘bother’ is not. Function was stated to reflect the degree of symptoms, 
whereas bother reflects the extent the symptoms impact the patient. My 
criticism of this area of research is patients can exaggerate or understate their 
usual sexual activity or failure to achieve erections. This may be because of 
embarrassment or shame or lack of understanding of the terminology. Other 
reasons for what Chang et al call ‘factors affecting patient responses’ could be 
the patient’s background, personality, age or level of education (10).A second 
criticism is the low incidence of reports of the use of oral erectile aids such as 
sildenafil (Viagra), at 9%. Today that figure may be significantly higher, reducing 
the reliance on vacuum devices or penile injections.  
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Helgason et al in 1996 (11) specifically examined the distress for prostate cancer 
patients. They compared the disease population with a similar reference 
population. They were asking if the patients would trade-off long-term survival 
for intact sexual function. In all ages, 19% of 299 patients would not accept 
treatment and 28% would only accept treatment if it prolonged life by ten or 
more years. The conclusion was that waning sexual function was the most 
common disease-specific reason for distress. A key finding was treatment was 
known to prolong life expectancy but was not necessarily what the patient would 
choose given the option. My criticism is this study relied on an instrument called 
“The Radiumhemmets Scale of Sexual Function”. The instrument was developed 
through successive in-depth interviews with just 30 prostate cancer patients. 
This group may not have been a representative sample of the population with 
prostate cancer.  
In 2015-16 the United Kingdom (UK) spent £220 billion on health and social care 
including benefits to support people with disabilities, or 11.5% of UK national 
income or 28.7% of total public spending(12). With this level of spending on health 
care, the question arises, what is produced and is there value for money? Other 
areas of the economy can have their output measured, such as industry like steel 
works. Costs are evaluated and profits generated. However, health services pose 
a challenge in terms of measuring ‘output’. It is possible to count and cost the 
products used, such as equipment or drugs, or the cost of a stay in hospital. 
However, these are intermediate costs. Health services are not valued in their 
own right but by their effects on health(2). The purpose of the NHS is not just to 
reduce harm but to promote health and social benefits in society as a whole.  
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1.1 Cardiovascular Disease Burden 
Roth et al in 2017 reported data on cardiovascular disease (CVD) in the Global 
Burden of Diseases Injuries and Risk Factors 2015 Study (13). They state CVDs are 
a leading cause of death in the world and a major barrier to sustainable human 
development. The number of CVD deaths per 100,000 of the population in 
Central Europe is 338, in high-income Asia Pacific it is 112 (the lowest) and in 
Central Asia it is 545 (the highest). Globally, the average is 286 per 100,000 of the 
population. Ischaemic heart disease (IHD) is a lack of blood to the heart muscle. 
IHD deaths per 100,000 of the population are 181 for Central Europe, 45 for 
high-income Asia Pacific (the lowest) and 336 for Central Asia (the highest). The 
global average is 142. The study reported that CVD deaths were declining in 
many high-income countries. However, the report also commented that the 
reduction in mortality from CVD has now reached a nadir and is no longer 
decreasing in high-income countries. The report authors speculate there may be 
several reasons for the flattening in the rate of decline in CVD deaths in 
developed countries, such as increases in obesity and air pollution and even 
changes in average air temperature although the authors state more research is 
needed in these areas. A criticism is this data is now several years out of date. 
Bhatnagar et al reported in “Trends in the epidemiology of cardiovascular disease 
in the UK” that  CVD was the second main cause of death (14). There has been a 
52% reduction in death rates between 1990 and 2013 and a 68% decline 
between 1980 and 2013. However, the authors note there has been little 
evidence of change in the prevalence of CVD in recent years. The report stated 
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that the number of patients registered at General Practice (GP) surgeries with 
coronary heart disease (CHD) has remained constant at around 3% of the 
population in England between 2004/05 and 2014/15. It also shows the number 
of hospital admissions for CHD in England has reduced from 428,262 in 2005/06 
to 401,007 in 2013/14. If you include all diseases of the circulatory system, 
including strokes, then the number of admissions increased from 1,244,004 in 
2005/06 to 1,401,232 in 2013/14. Bhatnagar et al(14) also reported that by 2013 
there was a seven-fold increase in the number of percutaneous coronary 
interventions (PCI) than 1993. The number of coronary artery bypass grafts 
(CABG) peaked in the 1990s but has since decreased by 33% as PCI is now the 
dominant treatment option.  
Luengo-Fernandez et al reported on the financial cost of CVD in the UK (15).  They 
state that CVD caused 40% of all deaths in the UK in 2012 (which includes 
strokes). The report authors attempted to estimate the economic cost of CVD 
and include healthcare costs, productivity losses and informal care costs. 
Informal case costs were defined as the opportunity cost of unpaid care. 
Included in healthcare costs were community health and social services, accident 
and emergency, day cases, inpatient stay, cardiac rehabilitation, outpatient 
services and drug costs. The estimated cost to the NHS in 2004 for CVD which 
includes strokes was £15.7 billion, or 21% of overall NHS expenditure. CHD was 
estimated to cost the NHS £3.45 billion in 2004, with 70% of this taken up by 
hospital inpatient care. The estimate for working days lost due to CVD incapacity 
was 69,346,572. The authors estimate the overall costs of CVD to the economy 
was £29.1 billion. They state the overall CVD related healthcare cost to the NHS 
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is 21% of the annual budget. It is the highest of any country in the European 
Union (EU). This cost was only surpassed by the estimated cost of mental 
illnesses. The authors stated the productivity loss costs were higher for CHD than 
for cerebrovascular accident (CVA) because more people die from CHD than CVA 
and that people die at a younger age from CHD than CVA.  A criticism of the 
report is both the age of the data and the difficulty of estimating informal costs. 
The authors state themselves the monetary value of the time carers forgo to 
provide unpaid care is not available directly. Some of this cost can be inferred 
from the proportion giving care above and below the age of 65 years, roughly the 
age of retirement, but this may be wildly inaccurate. 
1.2 Comparison between PCI and CABG 
Gershlick and Thomas in 2007 stated that there have been major changes in the 
management of symptomatic obstructive coronary artery disease in the last 10 
years (16). They state there has been a shift towards PCI and there has been 
debate about which is “better” by clinical outcomes and overall cost estimates. 
Weintraub et al in 2008 (17) for the COURAGE trial randomly compared 2287 
patients with stable coronary artery disease (CAD) to PCI plus optimal medical 
therapy (OMT) or to OMT alone. They showed that both groups showed 
improvements in health status. However, Gershlick and Thomas point out 
randomisation was performed after angiography and that most patients in the 
UK have angioplasty because of continuing symptoms despite OMT. They also 
pointed out that patients with left-main stem disease and left-ventricular 
dysfunction were excluded from the COURAGE trial and, therefore, if a similar 
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comparison was comparing CABG and OMT, there may be similar results. 
Another factor to be taken into account when comparing PCI and CABG is pre-
procedural assessment, which tends to be more rigorous before CABG (16). It was 
also noted that patency of grafts falls over time. Finally, Gershlick and Thomas 
point out several trial showing an ‘advantage’ for patients undergoing CABG 
were in the pre drug eluting stent (DES) period.  
Prof. Surruys et al reported the five-year outcomes of the ARTS trial (18). This trial 
randomised 1205 patients with multi-vessel CAD to PCI or CABG. This trial 
reported no significant differences in mortality, strokes or myocardial infarction 
(MI) between the two groups. However, there was a significant difference in 
major adverse cardiac and cardiovascular events (MACE), with 30.3% 
revascularisations in the PCI group and 8.8% in the CABG group. A criticism of 
this report is the age of the data, collected between 1997 and 1998, over twenty 
years ago. Since then, there have been developments in drug-eluting stents, 
catheter lab equipment and procedures, pharmacology and patient education. 
These factors will impact the differences in outcomes between the two allocated 
arms.  
Cohen et al reported the final results of the SYNTAX trial (19). This included 
patients with three-vessel or left main CAD. A total of 1800 patients were 
randomised to CABG or drug eluting stent (DES) DES-PCI. Over a five-year period, 
follow-up expenses – using American costs - were higher for the PCI group than 
the CABG group. This was caused by more frequent revascularisations and higher 
medicine costs. The conclusion was that CABG was both clinically and 
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economically advantageous. An obvious criticism is the use of American costs 
and the sole quality of life instrument was the EuroQol EQ-5D. However, this was 
used to calculate utility using a USA population. A full explanation of the EQ-5D is 
in chapter 3.  
1.3 PROMs 
Patient Reported Outcome Measures (PROMs) are defined by Black as 
instruments that seek to ascertain patients’ views on their symptoms, functional 
status and health related quality of life (20). Griggs et al (21) argue that PROMs 
“…have the potential to be as valuable to the clinical encounter as the 
stethoscope is to the physical examination”. They argue that there is potential in 
PROMs to restructure the clinical encounter and enhance accuracy of prognosis 
and help identify at risk individuals. By “at risk individuals” they mean patients 
whose PROM data is significantly different from the norm for that patient group. 
This could mean patients who are depressed or experiencing greater pain than 
the average reported by that clinical group. They argue that although there is 
always the potential for using PROMs for regulatory and administrative 
purposes, the clinical potential should not be overlooked. They conclude that the 
dual goals of value-based and patient-centred care are achievable if PROMs are 
embraced by clinicians and patients. A criticism of the report is that it was vague 
about the practicalities of incorporating PROMs in day-to-day clinical practice. 
This would be a massive change in culture and require huge investment.  
The United States has recommended the use of patient reported outcomes 
(PRO) in clinical trials and has stated “the use of PRO instruments is part of a 
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general movement toward the idea that the patient, properly queried, is the best 
source of information about how he or she feels” (22).  
1.4 Patient-Physician Discordance 
Patients’ and their physicians’ may have a different understanding of the 
patient’s quality of life. This discordance can be elicited from the use of PROMs 
data and comparing this to the physicians’ understanding and assumptions of the 
patients’ quality of life. Douglas et al reported on patient-physician discordance 
in goals of patients with advanced cancer (23). The study asked patients and their 
oncologists to complete a questionnaire at enrolment and every three-months 
until either the patients’ death or fifteen months. A simple visual analogue scale 
(VAS) of 100 points was used, with zero the worst and 100 the best quality of life. 
At baseline, 24% discordance was observed, and for patients who survived at 
their last interview there was also 24% discordance. At the last interview before 
death for patients who did not survive to fifteen-months there was 28% 
discordance whereas at first interview had been 70%.  The authors concluded 
there was a discrepancy between the goals of care of both oncologists and their 
patients. There was a deficiency of understanding between patients’ and their 
oncologists and this reflected a lack of what they called “high-quality 
communication and decision making” (23).  The authors conclude that the use of a 
simple tool such as VAS could lead to enhancing the communication between 
oncologist and patient and this in turn could lead to more appropriate treatment 
decisions and incorporating the patients’ and oncologist goals into the care plan.  
My criticism of this report is it was a single centre and enrolled just 11 
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oncologists. The problem with single centre studies if the generalisability of the 
results. If the 11 oncologists were all world leaders in their field this would not 
represent the average.  
1.4.1 Measuring Discordance: Cohen’s kappa 
There are several methods for measuring the agreement between two raters, 
but the most common is Cohen’s kappa (24). Cohen’s kappa measures the 
agreement between raters but takes into account the possibility of chance 
agreement. Kappa is intended to give the reader a quantitative measure of the 
magnitude of agreement between raters (25).  If a study measures a variable with 
only two possible states, such as dead or alive, then there will be high reliability 
between the raters. However, when there are finer discriminations reliability 
between the raters is harder to obtain. “Reliability of data collection is a 
component of overall confidence in a research study’s accuracy” (24). Kappa score 
can range from -1 to +1, where zero represents the agreement expected by 
chance, 1 represents perfect agreement .  
The formula for kappa is: k = Pr(a) – Pr(e) divided by 1- Pr(e) 
 Pr(a) represents the actual observed agreement and Pr(e) represents chance 
agreement. 
Weighted kappa can be used in cases where there are multiple categories. A 
weighted kappa can assign less weight to agreement as the categories are 
further apart. This means for example that a rating of zero by one rater and five 
by another could be assigned less weight than a rating of two by one rater and 
three by the other.  
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Cohen stated the kappa results could be interpreted as follows: ≤0 no 
agreement, 0.01 to 0.20 none to slight; 0.21 to 0.40 fair; 0.41 to 0.60 moderate; 
0.61 to 0.80 substantial and finally 0.81 to 1.00 almost perfect. Kappa is affected 
by prevalence of the findings under consideration. With rare findings, very low 
kappa values may not necessarily reflect low rates of agreement (25).  
 
Chapter 4 will discuss discordance in patient-physician reporting of the burden of 
angina experienced by patients.  
1.5 Categories of PROMs  
The systematic collection of PROMs data in the NHS began in 2009 and 
represented a recognition of the patient’s perspective in both the quality and 
effectiveness in health care(2). Initially data was collected in respect of four 
procedures, namely hernia repair, hip and knee replacement and varicose veins.  
The NHS is the first health care system in the world to routinely collect PROMs 
data and this could promote several initiatives such as informing patients, 
benchmarking performance, and linking payments to performance to name just a 
few (2).  
The Patient Reported Outcome Measurement Group, Oxford, in their report to 
the Department of Health in 2010 (8) state there are three broad categories of 
PROMs: generic, preference based and disease specific. Generic instruments are 
intended to be used across many health conditions. Preference based 
instruments are also broad but can be used for cost-utility analysis. Disease 
specific are concerned with a specific disorder such as angina or a disease 
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specific to a population such as adolescents or a symptom such as loss of 
hearing. PROMs are not designed to elicit patient’s satisfaction with their care. 
Black points out PROMs do not measure “outcomes” (20) but the patient’s health 
“state” at a moment in time. Sequential use of PROMs can indicate a change in 
the patient’s perception of their health over time, for example a year after a 
procedure. It is important to emphasise PROMs are not reporting on the 
experience of healthcare which could include how the patient was treated in an 
Outpatients Department.  
The Department of Health in its Guidance on the Routine Collection of Patient 
Reported Outcome Measures (26) state that a PROM is a measure of a patient’s 
health status or health-related quality of life. They go on to state they are 
typically short, self-completed questionnaires that measure the patient’s health 
status or health related quality of life at a single point in time.  
The Department of Health report High Quality Care For All (27) stated payments to 
hospitals will be conditional on the quality of care given to patients. The quality 
measures would include clinical outcomes and the patient experience and views 
about the success of their treatment. The report pointed out that the NHS 
budget in 1996/7 was £33 billion and in 2008/9 it was £96 billion. Obtaining 
value for money is important but evaluation of the effectiveness of interventions 
will include the patient’s perspective. The report gives examples of the use of 
PROMs as improvement in pain-free movement after joint replacement or 
returning to work after treatment for depression. 
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1.5.1 Preference Based PROMs 
Preference based PROMs are described as broad in content but also provide 
utilities or values regarding health (8). In chapter 3, I will present a detailed 
review of the PROM instruments I will use in this thesis. The Patient Reported 
Outcome Group Oxford list several PROM instruments aimed at coronary 
revascularisation (8). Their recommendation was the EuroQol Group EQ-5D 
instrument (EQ-5D) (28). This instrument contains two separate elements. The 
first consists of five questions concerning mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each of the questions has five options 
and the patient selects one for each question. The options are “I have no 
problems”, “I have slight problems”, “I have moderate problems”, “I have severe 
problems” and “I am unable to do my usual activity”. The second part is a VAS 
scale from zero to one hundred. Patients are asked to place a cross on the scale 
where one hundred represents the best possible health and zero the worst.  
1.5.2 Generic PROMs  
Generic PROMs are intended to be relevant to a wide range of patient conditions 
and the general population (8).In the category of generic based instruments, the 
Oxford Group recommend the Short Form 36 (SF-36) (29). This instrument consists 
of eight domains and thirty-five questions. The thirty-sixth question relates to 
health changes over a year. The domains are physical functioning, role-physical, 
bodily pain, general health, vitality, social functioning, role-emotional and mental 
health.  
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1.5.3 Disease Specific PROMs  
In the category of disease specific the recommendation was to use the Seattle 
Angina Questionnaire (SAQ) (30). This instrument contains five domains and 
nineteen questions. The domains are physical limitation, angina stability, angina 
frequency, treatment satisfaction and disease perception.  
1.6 Thesis 
In terms of thesis novelty, I will investigate how PROMs are used in 
interventional cardiology and whether there is agreement between clinicians and 
patients on patients’ quality of life. Bass et al pointed out that studies show 
clinician reported assessments tend to underestimate burden and severity of 
symptoms when compared with patient ratings (31). Discordance in assessing 
patients’ quality of life may be especially relevant in situations where symptoms 
are not directly observable by clinicians. This can include pain, fatigue, sexual 
dysfunction and emotional disorders (10). 
Chang et al point out that the use of PROMs has expanded and this reflects an 
increasing recognition of what they call “patient centredness” in high quality 
health care (10). They also point out that historically formal evaluations from the 
patients’ perspective have been undervalued. In terms of the potential value of 
PROMs, Cheng et al also point out there are a number of applications of 
high-quality data from the perspective of the patient. These include assisting the 
patient in making informed decisions about their care and allowing their 
clinicians in monitoring the patients’ perspective about their care (10).   The 
quality of healthcare can be monitored via PROM data and this in turn can 
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impact policy makers in decisions on reimbursement to hospitals. In clinical trials, 
PROMs can be used as a primary endpoint. There was an increase in the use of 
PROMs in oncology trials in the United States, rising from 27% in 2007 to 33% in 
2013 (32). 
1.7 Use of Stent or Surgery Trial Data 
My thesis analyses data collected as part of the Stent or Surgery Trial (SoS) (33). 
The SoS trial compared CABG with PCI. However, participants were all required 
to complete multiple PROMs at several timepoints. In conversation with one of 
the SoS trial Principal Investigators I was informed that the intention of collecting 
the PROMs data was for an in-depth analysis at a later stage. The intention was 
to compare different PROMs data by, for example, comparing generic versus 
disease specific. The objective was for the data analysis to be in the form of a 
higher degree for a student. However, the SoS Principal Investigator became 
involved in other high-profile research which caused delays in finding a student 
to undertake PROMs analysis.  
The SoS trial is discussed in Chapter 2. SoS was a randomised controlled trial  that 
compared percutaneous coronary intervention (PCI) with coronary artery bypass 
graft (CABG). The primary outcome measure was the rate of repeat 
revascularisation. The trial recruited patients from fifty-three centres in Europe 
and Canada and randomised nine-hundred and eighty-eight patients. Along with 
collecting clinical trial data, each patient was asked to complete several distinct 
PROMs at baseline, six and twelve-months.  
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Chapter 3 will discuss the various PROM instruments used. Chapter 4 
investigates discordance in reporting quality of life by both patients and by their 
clinicians who estimated their patients’ quality of life. I believe this analysis may 
be unique.  
Chapter 5 investigates two PROMs, the Seattle Angina Questionnaire (SAQ) and 
the EQ-5D and examines the degree of agreement between the two. I compared 
one aspect of the EQ-5D, the VAS with each of the five domains of the SAQ. I also 
examined the magnitude of change over twelve-months.  
Chapter 6 investigates correlation between a shorter, seven question version of 
the SAQ and the full nineteen question SAQ. A single summary score was 
calculated for both the short and full SAQ. I will compare the two scores at all 
three time-points using scatter plots. I will also compare the summary score for 
CABG and PCI patients again using a scatter plot. 
Chapter 7 investigates the advantages and disadvantages of questionnaires as a 
method of collecting data. I will examine issues around financial considerations, 
practicability, speed, scale and anonymity. I also examine participant fatigue, 
dishonesty and interpretation. Finally, I examine bias in questionnaires. 
The final chapter is a summary of this thesis with some key conclusions. 
The next chapter will discuss the Stent or Surgery Trial.  
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 Stent or Surgery Trial 
The Stent or Surgery Trial (SoS) (33) was a comparison between stent assisted PCI 
versus CABG for patients with multivessel disease coronary artery disease (CAD). 
PROMs data from the SoS trial forms the basis of this thesis. SoS was a 
multi-centre international trial in fifty-three centres in Europe and Canada. The 
primary outcome measure was the rate of repeat revascularisation. Nine-
hundred and eighty-eight patients were randomised. There was a minimum of 
one-year follow-up for all patients. The results have been reported elsewhere (33). 
In summary, 21% of patients in the PCI group required repeat revascularisation 
compared with 6% in the CABG group. There were 12 deaths in the PCI group 
and 4 in the CABG group.  
2.1 SoS Protocol 
All trial operators were required to perform optimal revascularisation following 
their local best practice. CABG could be performed either on or off-pump. Each 
trial centre could use stents of their choice. Any PCI could be performed as a 
single or two stage procedure, provided a two stage was completed inside 
twenty-eight days. All clinical and adverse events were followed from the point 
of randomisation. Follow-up visits were performed at six- and twelve-months 
post randomisation. All patients were followed up for at least one year. The 
primary outcome measure was the rate of repeat revascularisation. There were 
several secondary outcomes. These were death, q-wave myocardial infarction, 
symptoms of angina, cardiac medication requirements, all-cause mortality and 
left-ventricular function. Symptoms of angina were assessed using the Canadian 
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Cardiovascular Society classification (CCS). Left-ventricular function was assessed 
by echocardiography (ECHO) and was analysed independently. Repeat 
revascularisations were any coronary revascularisation performed after the index 
procedure. If the procedure was planned as two-stages, then a repeat 
revascularisation was defined as an intervention performed on a lesion treated 
during the first stage.  Due to the nature of the intervention allocated by 
randomisation it was not possible to blind either the trial clinicians or patients to 
the allocation.  
Recruitment took place between November 1996 and December 1999. Patients 
needed to be symptomatic and have multivessel CAD and should be suitable for 
either PCI or CABG in the opinion of a surgeon and interventionalist. 
Randomisation was centre-specific and block sizes of two, four and six were 
used. The primary outcome was analysed using Cox proportional hazard models. 
Chi squared was used to analyse the proportions of patients with no angina (CCS 
= 0) or any degree of angina (CCS > 0).  
2.2 SoS Results 
Analysis was on an intention to treat basis. The mean age of patients was 61 
years and 79% were men. Most repeat revascularisations occurred within the 
first year following randomisation. Of those patients initially randomised to PCI, 
9% crossed over to CABG. The number of deaths in the SoS trial was small at just 
16 (4 CABG, 12 PCI group). However, it was stated that in the PCI group, there 
were eight deaths due to cancer and one in the CABG group. This was attributed 
to chance. All-cause mortality was reported and was also classified as cardiac, 
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other vascular, non-cardiovascular and unclassified. The low rate of death in the 
CABG group could be a product of the “favourable” coronary anatomy and 
surgical risk profile. There was no difference in the composite outcome of death 
or non-fatal Q-wave myocardial infarction. Severe angina, classified as CCS class 
3 or 4, was present in 46% of patients. In the PCI group, 85% of patients received 
a single procedure rather than a two-stage procedure. In those patients who 
were allocated a PCI, 94% of the lesions attempted were successfully 
revascularised.  Of those patients allocated to CABG, 3% were performed 
without cardiopulmonary bypass (off-pump). Of those patients allocated to PCI, 
21% required additional revascularisation over a median period of two years. 
This compares to just 6% in the CABG group for the same period. Although 17% 
of patients randomised to PCI required revascularisation in the first year, this is a 
reduction when compared to the era of balloon angioplasty.  
2.3 Trial Conclusions 
The SoS trial concluded there was a “survival advantage” with CABG and the use 
of coronary stents reduced the need for revascularisation compared to previous 
studies. However, this was a time of significant emerging developments such as 
drug eluting stents (DES) and glycoprotein IIb/IIIa antiplatelet agents along with 
new oral antiplatelet agents such as clopidogrel. These were considered to have 
significant potential to reduce revascularisation rates. The SoS trial required 
patients to be suitable for revascularisation by either CABG or PCI. This limited 
the trial population to a minority of patients. There remained the possibility that 
individual cardiologists or surgeons may be unwilling to submit their patients to 
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randomisation. Centres did also report difficulty in obtaining consent because 
patients were required to accept two very different treatment options when 
one, CABG, was more invasive than the other. The trial authors also estimated 
that centres only randomised between 3-6% of eligible patients. 
2.4 Other Trials in This Period 
Several other trials in this period compared PCI to CABG. Serruys et al compared 
CABG and stenting (PCI) for the treatment of multi-vessel disease (ARTS Trial) (34). 
They found at one year there was no significant difference between the two 
groups in terms of death, strokes or myocardial infarction, the primary clinical 
end point. They also found PCI is associated with a greater need for repeat 
revascularisation. 
King et al in the EAST trial - in the era before stents were routinely used - found 
that PCI and CABG did not differ significantly in respect of their composite end-
point (death, Q-wave myocardial infarction and a large ischemic defect)  after 
three-years (35). The authors did point out the clinical usefulness and long-term 
prognostic value of their composite end-point had not been established. They 
did not report on any quality-of-life measures in the trial. However, at three 
years there was a greater proportion of revascularization in the PCI group, and 
angina was also more frequent in the PCI group. Weintraub et al also reported on 
the EAST trial and included data on quality of life (36). They reported almost two-
thirds of patients reported good or very good health but that there was a “strong 
trend” for CABG patients to believe they had recovered completely compared to 
the PCI group.  
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The RITA trial (37) - also before stents were routinely used - found that recovery 
from CABG takes longer than PCI but CABG leads to less angina. However, there 
was no significant differences in risk of death or MI. The BARI trial (38) followed up 
patients for five years following either CABG or PCI. The trial found that patients 
who were randomised to PCI were not significantly compromised in terms of 
five-year survival by comparison to CABG patients although there were more 
revascularisations. However, if the patient was diabetic, five-year survival was 
significantly better for the CABG group of patients. 
The SoS trial asked patients to complete several PROMs at three time-points. The 
time-points were baseline, six and twelve-months post-randomisation. The 
PROM instruments completed were the Short-Form 36 (SF-36) (39), the SAQ (30), 
the Cardiac Health Profile (CHP) which includes the Canadian Cardiac Society 
(CCS) (40) assessment of angina burden and EQ-5D (41) . There is a full discussion of 
PROM instruments in the next chapter.  
2.5 SF-36 
The SF-36 is categorized by the Patient-Reported Outcome Measurement Group, 
Oxford (8) as a generic instrument. This means it is applicable to many conditions 
or patient groups. There are thirty-five questions in eight separate domains into 
which data is grouped. A thirty-sixth question compares health with a previous 
year, making thirty-six questions in total. The domains are physical functioning; 
role physical; bodily pain; general health; vitality; social functioning; role 
emotional health and mental health. The questions have a categorical response 
and scoring uses a weighted scoring algorithm. Each domain is scored separately, 
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and the scores transformed into a range from zero to one hundred. Higher scores 
indicate better health. In the SoS trial, 947 patients completed the SF-36 at 
baseline, 916 at six-months and 919 at twelve-months.  
2.6 Seattle Angina Questionnaire 
The SAQ was developed by Spertus et al as a disease specific functional status 
measure (30). It consists of nineteen questions in five domains. The domains are 
physical limitation; angina stability; angina frequency; treatment satisfaction and 
disease perception. Each question is assigned an ordinal value with higher scores 
indicating better function. Each domain is scored separately and transformed 
into a score between zero and one hundred. There is no ‘global’ score. The SAQ 
measures the domains over the previous four-weeks. In the SoS trial, 945 
patients completed the SAQ at baseline, 918 at six-months and 917 at one-year 
post-randomisation.  
2.7 Cardiac Health Profile 
The Cardiac Health Profile is a disease specific questionnaire (42). It consists of 
three parts. These are the degree of angina assessed using the CCS scale (40), 
quality of life (sixteen questions) and psychological cost-benefit (two questions). 
I will examine the use of CCS which was reported by patients and by clinicians 
reporting on their assessment of the same patient’s angina burden in Chapter 4. 
In the SoS trial, 959 patients completed the questionnaire – including the CCS - at 
baseline, 921 at six-months and 930 at twelve-months post-randomisation. 
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2.8 EuroQol EQ-5D 
The EQ-5D is a generic instrument consisting of five domains and a VAS. The 
EQ-5D was intended to be used in conjunction with disease specific instruments 
(8). The five domains are anxiety/depression; mobility; pain/discomfort; self-care 
and usual activities. Societal valuations, which are country specific, were used to 
establish weights for the index score. The possible range is -0.59 to 1.00. A score 
of -0.59 is a state worse than death and 1.00 equates to the best possible health. 
The VAS is a single scale from zero to one hundred where zero is the worst and 
one hundred the best imaginable health. It was intended that both the index 
score and VAS would be reported. In the SoS trial, 886 patients completed the 
EQ-5D at baseline, 892 at six-months and 906 at twelve-months 
post-randomisation. 
2.9 SoS One-year Follow-up 
The one-year follow-up results from the SoS trial were published in 2003 and 
made specific reference to the SAQ data (43). The trial found that scores for 
physical limitation, angina frequency and quality of life improved significantly at 
six-months for both PCI and CABG. The PCI group of patients did have a greater 
number of interventions. However, overall treatment satisfaction not differ 
significantly between the CABG and PCI groups(43). 
There have been several publications following the original results from the SoS 
trial. These include Neuropsychological outcomes (44), the impact of age on 
outcomes (45) and the impact of acute coronary syndromes (46). 
The next chapter discusses PROM instruments in more detail. 
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 PROM Instruments 
The earliest randomised clinical trials - with a focus on the major diseases of that 
time - tended to report mortality as their primary outcome.  Later, studies began 
to examine other adverse events, testing therapies with the potential to, for 
example, reduce the rate of stroke or myocardial infarction.  With improvements 
in public health, general standards of medical care and the fact that new 
treatments now need to demonstrate incremental benefit over existing, proven 
therapies – the absolute gain with a new approach may be modest.  This creates 
problems in trial design. To secure the statistical power required to demonstrate 
treatment differences with precision would require large numbers of outcome 
events. This in turn demands either large numbers of patients, or prolonged 
follow-up or a study population with a very high baseline risk.  These factors 
increase the complexity, cost and timeframe of studies.  There has been a move 
towards the development of composite outcomes. For example, the combined 
rate of death or stroke or myocardial infarction, MACE events. This is a means of 
increasing event rates and creating studies that can be performed in a timely 
manner, with a reasonable budget. 
It is important to note however that the vast majority of studies report outcome 
in terms of the rate of subsequent, observed clinical events.  The impact of these 
events, and importantly the treatments that are applied, on the overall 
well-being of patients has often been neglected. A desirable clinical outcome 
does not necessarily equate to an improvement in the patients’ quality of life .  
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PROMs are a means for patients to report their symptoms, health related quality 
of life or satisfaction with treatment (47). This reporting is usually performed 
independent of their clinician or other caregiver. This information can 
supplement clinical data such as mortality or specified clinical events such as the 
rate of strokes. PROMs can in turn help to inform clinical decisions, disease 
management or,  on a large scale, policy in healthcare.  
PROMs can measure a specific symptom such as pain or depression, knowledge 
of a condition, function such as limb movement, compliance to therapy or health 
related quality of life. The World Health Organisation (WHO) defines Quality of 
Life (WHOQoL) as “an individual's perception of their position in life in the context 
of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns. It is a broad ranging concept affected in a 
complex way by the person's physical health, psychological state, personal 
beliefs, social relationships and their relationship to salient features of their 
environment” (48). The WHOQoL emphasises the individual’s perception of 
themselves and their views of their wellbeing. The WHO state that diabetes 
involves poor body regulation of blood glucose which is well understood. 
However, the effect of illness on the perception individuals have of their social 
relationships, working capacity and financial status has received little attention 
(48). Quality of life could be said to address the patient’s need for fulfilment as 
opposed to symptom relief.  
The name patient reported outcome measures is a misnomer as the patient is 
not reporting ‘outcomes’ but is answering a series of questions relating to their 
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quality of life at the current time or over the last month in the case of some 
scoring systems (20). 
PROMs can provide high quality quantitative data to examine the effects of an 
intervention on the patient’s day to day life and their functioning in society. Data 
can be used to inform discussions between patients and their clinicians. These 
discussions may focus on the clinical benefits of continuing treatment as 
opposed to the patient’s belief concerning the value to themselves. One less 
obvious use of PROM data can be to inform funding decisions made by Clinical 
Commissioning Groups (CCG). Clinical effectiveness of a procedure on its own is 
not necessarily sufficient to warrant its continued funding. In the United 
Kingdom the National Institute for Health and Clinical Excellence (NICE) uses the 
EQ-5D to calculate quality adjusted life years (QALY). The EQ-5D asks five 
questions about aspects of daily living and also contains a visual analogue scale. 
A QALY is calculated using two factors. These are length of life and quality of life 
(49).  Weinstein et al (50) point out there are several assumptions made in 
calculating QALYs. These can be summarised as: value is measured in terms of 
preference, preferences measured across individuals can be aggregated and used 
for the whole group and a QALY is the same for anyone.  
Lord Darzi in his report in 2007 recommended PROMs should have a greater 
roles in the NHS (7). As a result, from 2008, the Standard NHS Contract for Acute 
Services  included a requirement to collect PROMs for four surgical procedures. 
These were hip or knee replacement, groin hernia and varicose vein procedures.  
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Hamilton et al reported on the determinants of patient satisfaction following 
lower limb joint replacement (51). This study involved a large cohort and is a good 
example of the use of PROMs to influence healthcare delivery. Their study 
followed 4,709 patients over a four-year period in a single United Kingdom 
hospital involving multiple surgeons. The authors pointed out that although 
there was rapid access to surgery and fewer complications, satisfaction with 
services had declined over several years. As joint replacement was a high-volume 
service and was closely monitored, this was a good choice to examine this 
paradox.  The trial used the Oxford Hip or Knee Score and Medical Outcomes 
Study Short Form 12 (SF-12) PROM. These were completed at baseline, six- and 
twelve-months post-surgery. The authors pointed out the concept of 
“satisfaction” is widely used in consumer marketing. They defined satisfaction as 
“an attitude like judgement following an act based on a series of 
product-consumer interactions” (52). They go on to say satisfaction has been used 
as a healthcare performance indicator for surgery in the UK and Europe (53).  
The authors also point out that outcome and satisfaction, although associated, 
are not the same metric. The authors make the statement “PROM scores are 
useful tools for the assessment of clinical outcome in which they focus primarily 
on pain relief” (51). It could be that failure to meet “optimistic expectations” is 
associated with dissatisfaction following surgery. Five factors were identified that 
explain the patients’ overall satisfaction following surgery. These were meeting 
preoperative expectations, satisfactory pain relief, the patients’ subjective 
hospital experience, pre-operative physical status and finally twelve-month 
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physical status. They also found that factors such as patient age, gender and 
other comorbidities did not impact satisfaction.  
3.1 Categories of PROMs 
PROMs can be broadly categorised into three groups. These are preference 
based, generic health states,  and condition or population specific instruments (8). 
A generic instrument can be completed by a large range of people regardless of 
their medical condition, age or gender. As such generic instruments such as the 
short form 36 (SF-36) have been used in multiple trials in cardiology.  
A preference-based instrument is broadly similar in that it can be applied to a 
range of conditions or population groups. However, the additional advantage is 
preference-based instruments can be used to calculate utilities which can then 
be used to calculate quality adjusted life years (QALY) for cost utility analysis. An 
example of such an instrument and one of the most commonly used is the 
European Quality of Life instrument EQ-5D.  
Condition specific instruments focus on a particular condition or disease, a 
particular population, a symptom, or a function.  An example is the SAQ. This 
nineteen question, five domain questionnaire was intended to measure both 
physical and emotional effects of coronary artery disease over the previous four 
weeks. An example of one PROM from each category will now be discussed. 
These three were selected because they are commonly used in clinical research 
and two - EQ-5D and SAQ - are discussed in detail in other chapters in this thesis. 
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3.1.1 Preference Based: EQ-5D 
The EuroQol Group consists of a network of researchers and was established in 
1987. The EuroQol Group describe the EQ-5D as “a standardised measure of 
health status developed by the EuroQol Group in order to provide a simple, 
generic measure of health for clinical and economic appraisal” (28).  The 
advantages of the EQ-5D are that it provides a descriptive profile and single 
index value for health status. This can be used in both health care and population 
health surveys. It can be completed by the participant themselves, by telephone 
or face to face interviews with healthcare professionals. It takes a few minutes to 
complete and is undemanding for participants.  
The EQ-5D-3L was introduced in 1990. There were two pages, one consisting of 
five questions with multiple-choice answers. The second page contained a VAS. 
The five dimensions cover mobility, self-care, usual activities, pain and 
discomfort and anxiety and depression. There were three levels of response to 
each question. These are “I have no problems with…”, “I have some problems 
with…” or “I have extreme problems with…”. The VAS is a vertical scale from zero 
to one-hundred. The zero is labelled “Worst imaginable health state” and the 
other extreme is labelled “Best  imaginable health state”. The respondent is 
asked to place a cross on the scale that represents their health state at that 
moment in time. This represents the individual ‘quantitative’ measure by the 
respondent. This differs from the first part, the multiple-choice questions which 
eventually produce an index value weighted on a country basis.   
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It was intended that the EQ-5D would be supplemented by other disease specific 
instruments (8). Weights or data-sets were established in specific countries which 
were based on societal valuations of health and these weights are used to 
calculate an index score. The data-sets include the United Kingdom (UK), several 
other European countries and the United States of America (USA). The score can 
be in a range from -0.59 to plus 1. The minus score represents a state worse than 
death and a score of one represents the best imaginable health state. An 
example of a state worse than death could be a persistent vegetative state.  
In 2005 the EuroQol Group setup a Task Force to improve the sensitivity of the 
EQ-5D and reduce ceiling effects. This is when a high proportion of respondents 
score at the high-end of a scale making it difficult to discriminate among 
respondents (54). If, preoperatively, a respondent scores at the high end of the 
scale there is little room for improvement postoperatively. Conversely, those 
who score at the low end of the scale there is little room for a lower score 
postoperatively. This makes it difficult to discriminate change at the extremes. 
The Task Force made no change to the number of dimensions, which remained 
at five. However, the number of levels of severity would be increased from three 
to five. The Task Force showed that five levels of severity would increase 
sensitivity (and the discriminatory power) whilst maintaining its feasibility and 
reducing ceiling effects (28).  The new levels would be: “I have no problems…”, “I 
have slight problems…”, “I have moderate problems…”, “I have severe 
problems…” and “I have extreme problems…”. As with the three-level response, 
each response represents a one-digit number from one to five. This results in a 
five-digit number ranging from 11111 (the lowest score) to 55555. These 
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numerals have no intrinsic arithmetic properties but are used to calculate a 
single index value.   
The index value is calculated by using a “Crosswalk Index Value” calculator, 
provided by the EuroQol Group via their website https://euroqol.org/. The 
individual domain scores are pasted into the calculator, the correct country 
selected along with the total number of respondents. This then produces the EQ-
5D profile (the five-digit number such as 12345) and the index value. This differs 
for each country. With five possible responses and five-levels, there are 3,125 
possible health states. The best possible in nearly all countries is one, the 
exception being Zimbabwe where it is 0.9. The worst possible score, represented 
by 55555, is -0.594 for the UK but -0.109 for the USA. This shows that each 
country has a different expectation of what constitutes the worst or best 
imaginable health state. The EQ-5D can be used to calculate quality adjusted life 
years (QALYs). A QALY takes into account both quantity and quality of life (55). The 
EQ-5D has been translated into over 170 languages (28).  
3.1.2 Disease Specific: Seattle Angina Questionnaire 
The SAQ was developed by Spertus et al in 1995 (30). The SAQ measures both 
physical and emotional effects of coronary heart disease but only over the 
previous four weeks. The rationale for the development of the SAQ was that 
although clinical endpoints such as treadmill tests or left-ventricle function were 
important, they correlate poorly with the patient’s functional status. Improving a 
patient’s functional status is an important goal of any intervention. Spertus et al 
reasoned that quality of life domains should quantify the level of exertion as 
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patients tend to alter their level of activity to minimise their angina discomfort. 
They also wanted to measure the frequency of angina and the patient 
satisfaction with their treatment, alongside a functional measure to assess the 
patient’s perception of how disease limits their life (30).  
The SAQ measures nineteen items in five domains. These domains are physical 
limitation, angina stability, angina frequency, treatment satisfaction and disease 
perception (now known as quality of life). The largest number of questions 
appear in the physical limitation domain. Nine questions are grouped into three 
types of activity, from the lowest exertion such as dressing yourself, the medium 
exertion such as gardening to the highest exertion such as running or jogging. 
Activities were selected to minimise differences in socioeconomic groups. Each 
domain is scored separately, and the score transposed into a score from zero to 
one hundred. There is no overall single score.  
In developing the SAQ the researchers studied four distinct patients groups. 
These were patients undergoing treadmill tests, outpatients with self-reported 
coronary artery disease, patients with initially stable coronary artery disease and 
patients undergoing percutaneous coronary angioplasty. They tested for validity, 
responsiveness and reproducibility. The authors suggested there were two 
primary advantages of the SAQ. The first was that it quantifies a broader range of 
disease effects than the CCS classification, the Duke Activity Status Index (DASI) 
or the Specific Activity Scale. The second was that the SAQ physical limitation 
scale captures activity that is specific to coronary artery disease unlike other 
instruments such as DASI or Short Form 36.  
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The SAQ has been used frequently in clinical trials over the years and used as a 
performance measure in assessing quality of care (56). There are however several 
limiting factors in the use of the SAQ. One is its length at nineteen questions and 
the second is the lack of a single ‘global’ score. A single number would aid both 
physicians and patients’ understanding of any changes over time. Another 
limitation is the original validation of the instrument involved mainly elderly 
males from a Veterans Affairs medical centre, and this may limit the 
generalisability of the SAQ. A more general limitation of any disease specific 
instrument, although not specifically the SAQ, is the effect of other comorbidities 
on the patients’ responses. A patient with rheumatoid arthritis and coronary 
disease may have a flare up of their arthritis but no change in their CAD. This 
could be interpreted in the score as a worsening of their CAD. A shorter, seven 
question version of the SAQ has been developed as a response to the limitations 
mentioned above (57)and is discussed in detail in Chapter 6. 
3.1.3 Generic: Short Form 36 
The SF-36 is a generic instrument measuring both physical and mental health. 
The development of the SF-36 was driven by a recognition of the need to 
measure population health and not focus on a specific disease, condition or 
population group. It was developed to assess basic human values that are 
fundamental to everyone’s functional status (39). It does not target either a 
specific age group or disease but is intended for use by the general population. 
Its development was a result of recognition of the need to incorporate 
standardised health surveys in clinical trials and the development of general 
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population health surveys in the 1980s (39). The SF-36 was preceded by the 
Medical Outcomes Study (MOS), which was a four-year longitudinal study of the 
variations in practice styles and health outcomes of chronically ill patients (58). 
MOS measured forty health questions and involved twenty-three thousand 
patients from three-hundred and sixty-two clinicians and one-hundred and 
sixty-one mental health providers (39). These in turn formed the basis for the 
shorter SF-36 which was first available in 1988. 
The SF-36 records patients’ responses in eight domains. These domains were 
chosen as they most accurately reflect disease and health conditions and those 
most widely measured by other health surveys (39).  The eight domains can be 
split into two groups of four. These are physical health and mental health. The 
four domains representing physical health are physical functioning, role physical, 
bodily pain and general health. The four domains representing mental health are 
vitality, social functioning, role emotional and mental health. There are ten 
questions that relate to physical functioning. In this domain the desire was to 
represent the extremes of activities, such as lifting, climbing stairs, kneeling or 
walking moderate distances. Role physical , four questions, examines health 
related role limitations. An example would be reductions in time spent in work or 
other usual activities. Bodily pain, two questions, looks at how pain interferes 
with work and its intensity. General health contains five questions and 
concentrates on the respondents view on their expectations. Vitality refers to 
levels of energy over four questions. Social functioning, two questions, focuses 
on both the quantity and quality of social functioning. Role emotional, three 
questions, examines happiness, stress and emotional problems. Mental health 
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asks five questions about the respondents feelings, such as feeling downhearted 
or being nervous. There is one question that asks about how the respondent’s 
health compares to a year ago.  
The SF-36 is scored in several stages (59). First, groups of questions are assigned a 
value of between zero and one hundred, depending on the actual score of the 
question. For example, a score of 1 for individual items in the group of questions 
is assigned a score of 100. A high score denotes a more favourable health state. 
The second stage is to average the items together to create each individual scale. 
Blank fields are ignored. 
Although the SF-36 is ubiquitous and familiar to many researchers there are a 
number of limitations. In a study of nursing home residents, Andresen et al (60) 
found skewed scores for some scales. This, they suggested, may limit the SF-36 
to respondents with higher cognitive and physical functioning than typical 
nursing home residents. An instrument aimed at the general population and 
reporting on such a wide range of physical and mental health factors may not be 
responsive to a change in one aspect of the patients’ condition, such as angina. If 
the patient already has multiple comorbidities such as severe arthritis and back 
pain, a small improvement in the angina burden following revascularisation may 
not be reflected in the SF-36 score. The ‘signal’ from angina pain is lost in the 
‘noise’ of other chronic pain and discomfort. 
3.1.4 PROMs Measure Different Aspects of QoL  
It is important to understand that the PROMs reviewed above measure different 
aspects of a patient’s QoL. EQ-5D is broad in its scope, applicable to a wide range 
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of the population and can be used to calculate QALYs. The two parts, the five 
domains and VAS are intended to be used together although they measure 
different aspects of the patient’s QoL. The EQ-5D was intended to be used in 
combination with a disease specific instrument (8). By contrast, the SAQ was 
developed to measure quality of life for patients experiencing angina. It is 
specific to a population with known heart disease. Unlike the EQ-5D, there is no 
country specific calculation of the domain scores. The SF-36 is generic and can be 
used in a large population of healthy people. It attempts to measure both 
physical and mental health and to reflect other health surveys (39).  
The CCS scale for reporting angina symptoms is used in clinical trials (40) but is not 
strictly a PROM. It is predominately completed by physicians to rate their 
patient’s functional status and is not generally completed by patients 
themselves. CCS is part of the Cardiac Health Profile which is a PROM.  
The next chapter will discuss discordance in the reporting of patients’ quality of 
life between patients’ and their physicians. 
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 Discordance Between Physician and Patient 
4.1 Background 
This chapter examines discordance between patients and physicians in reporting 
of angina symptoms before and after revascularisation.  Primary outcomes in 
studies examining revascularisation for coronary artery disease usually report the 
rates of occurrence of subsequent adverse events.  These include mortality, 
subsequent  myocardial infarction and the need for additional unplanned 
revascularisation (2). 
There has been increasing recognition of the value of PROMs in the evaluation of 
treatment effect, symptom burden and quality of life. (8, 20, 26, 61). There is, 
however,  limited work comparing the reporting of functional improvement by 
patients and clinicians following coronary revascularisation.  
Revascularisation procedures aim to restore or improve blood flow to the heart 
muscle and include CABG and PCI. Revascularisation can have a prognostic 
benefit in certain patterns of more advanced disease or when performed in the 
setting of an acute coronary syndrome. Most procedures, however, are 
performed to reduce angina symptoms (17, 62)  
4.2 Literature Review 
This chapter builds upon a research paper published by Kemp et al in 2019 (63). A 
literature review for this chapter was further updated in July 2020. An iterative 
process was used to refine the search string. The final search string used was as 
follows: "Patient physician discordance" OR "patient and physician reporting" OR  
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"Patient and physician agreement" OR "Patient-reported symptoms and their 
documentation" OR "Patient and physician discordance" This returned twenty-
one results. These were downloaded into a spreadsheet and each was then 
reviewed for relevance. This identified three articles which are discussed in 
detail. The remaining eighteen (Table 1) are discussed in summary form. 
 
Lead author Title Cohort PROM Used Test Author conclusions 
      
Barton Patient-physician 
discordance in 
assessments of global 
disease severity in 
rheumatoid arthritis. 
 
223 Health Assessment 
Questionnaire, Patient 
Health Questionnaire (9 
item) for depression, VAS 
for global disease severity 
 
1 sample t-test Nearly one-third of 
RA patients differed 
from their physicians 
to a meaningful 
degree in assessment 
of global disease 
severity. Higher 
depressive symptoms 
were associated with 
discordance. Further 
investigation of the 
relationships 
between mood, 
disease activity, and 
discordance may 
guide interventions 
to improve care for 





discordance in global 
assessment in early 
spondyloarthritis and 
its change over time: 
the DESIR cohort. 
 
702 BASDI (Bath Ankylosing 
Spondylitis Activity Index) 
and SF-36 
 
Paired t-test Discordance was not 
a stable trait, 
indicating 








Discordance in Global 
Assessment in 




460 Health Assessment 
Questionnaire (HAS) and 
Disease Activity Index for 







concerned 29.1% of 
these 
patient/physician 






domains of health. 
Discordance was 
more frequent in 
patients in remission, 
indicating more work 
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Lead author Title Cohort PROM Used Test Author conclusions 
      
Desthieux Patient-Physician 







11879 VAS  Discordance in global 
assessment was most 
frequently defined as 
a difference of 3 
points or more; even 
with such a stringent 
definition, up to half 
the patients were 
found to be 
discordant. The long-
term consequences 
of this discordance 
remain to be 
determined. 
 




between patient and 




1090 European Organisation for 
Research and Treatment of 
Cancer (EORTC) and QLQ-30 
 
Cohen’s kappa Subjective toxicities 























was on satisfaction 




patients' level of 
satisfaction. 
Douglas Patient-physician 
discordance in goals 
of care for patients 
with advanced cancer. 
378 VAS Chi sq Fishers 
exact 





respect to goals of 
care. Early use of a 
simple visual 
analogue scale to 
assess goals of care 
can inform the 
oncologist about the 
patient's goals and 
lead to delivery of 
care that is aligned 
with patient goals. 
P a g e  52 
 
Lead author Title Cohort PROM Used Test Author conclusions 
      





patient and physician 
reporting of risk-
related previous 
history in NSAID users 
from the CADEUS 
study. 
 
26618 Prescriber questionnaire Multivariate 
analysis 
The study showed 
that a substantial 
proportion of 
prescribers seemed 
unaware of the 
presence of risk 
related PMHs that 
the patient reported 
when asked. 
 




Disease Activity Index 
in patients with axial 
spondyloarthritis. 
50 BASDAI Interclass 
coefficient 
Results could prompt 
the scientific 
community to revise 
outcomes or at least 
provide clear 
recommendations on 
the optimal way to 
collect it.  
Henderson Patient and physician 
reporting of 
symptoms and health-
related quality of life 
in trials of treatment 
for early prostate 
cancer: considerations 
for future studies. 
 SF-12 recommended in 
review 
 Although novel 
therapies may 
produce different 
toxicities, the current 
recommendations 
should help to 
produce trial 
protocols that will 
allow comparable 
data to be generated 










adherence to inhaled 
controller medication: 
a cross-sectional 
analysis of two 
cohorts. 














needed to improve 
patient-physician 
agreement. 
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Lead author Title Cohort PROM Used Test Author conclusions 

















during an office visit. 
Sonnenberg Personal View: 
Patient-physician 
discordance about 
benefits and risks in 
gastroenterology 
decision-making. 
   In instances of 
potential 
complications 
associated with risky 
medical 
interventions, 
patients may receive 
less medical therapy 
in exchange for more 
procedural safety. 
Tago Influence of large joint 
involvement on 
patient-physician 




analyzed by a novel 
joint index. 
12043 Novel joint indices Multivariate 
logistic analysis 
RA care providers 
should focus on pain 
and functional 
disability to decrease 
PGA-PhGA 
discordance. High 










perception of disease 
activity by patients 
with RA and their 
physicians. 
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Lead author Title Cohort PROM Used Test Author conclusions 
      
Thomas Patient and physician 
agreement on 
abdominal pain 
severity and need for 
opioid analgesia. 
30 VAS Cohen’s kappa Overall, patients and 
physicians agreed on 
the question of 
whether pain was 
sufficient to warrant 
opioids in 71 of 90 
(78.9%) assessments; 
the corresponding 
kappa statistic of .57 
indicated moderate 
agreement (P < 




agree on whether 
opioids are 
warranted for 
abdominal pain, have 
important 
implications for 
further research on 
ED analgesia in this 
population. 
Tory Patient and physician 
discordance of global 
disease assessment in 
juvenile 
dermatomyositis: 
findings from the 




639 Disease Activity Core Sets, 
Patient/Parent Global 
Activity Assessment Score 
(PF gVAS), Physician Global 








PF and MD gVAS was 
common in this JDM 
cohort. Overall, 




(PRO) scores, while 




suggests PF and MD 
assessments of gVAS 
may be measuring 
different aspects of 
disease, highlighting 
the importance of 
integrating PROs into 
clinical practice and 
research. 
Wang (2019) Factors associated 
with patient-physician 
discordance in a 
prospective cohort of 
patients with psoriatic 
arthritis: An Asian 
perspective. 
 
142 SF-36  Increased age, higher 
fatigue levels, higher 
pain score  and 
poorer mental health 
may explain 
underestimation of 




disease activity may 
be explained by 
higher swollen joint 
counts. 
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Lead author Title Cohort PROM Used Test Author conclusions 
      
Wang  (2018) Factors associated 
with patient-physician 
discordance in a 
prospective cohort of 
patients with psoriatic 
arthritis: An Asian 
perspective. 
142 Patient Global Assessment 
(PGA)using VAS scale, 
Physician Global 
Assessment (PhGA) 11 point 




Increased age, higher 
fatigue levels, higher 
pain score  and 
poorer mental health 
may explain 
underestimation of 




disease activity may 
be explained by 
higher swollen joint 
counts. 
 
Table 1 Summary of eighteen articles derived from literature search  
4.2.1 Pakhomov et al 
Pakhomov et al (64) discussed agreement between patient reported symptoms 
and how they were documented in medical records. The main symptoms of 
interest were chest pain, chest pressure, shortness of breath/dyspnoea and 
cough. They used two sources of information. These were patient provided 
forms and the electronic medical record for each patient identified by the use of 
natural language processing (NLP), regardless of whether the patient was an 
inpatient or outpatient. This was a convenience sample of 121,891 patients. A 
convenience sample is when subjects are enrolled according to their availability 
and accessibility (65). It is quick, inexpensive and convenient. With each of the 
symptoms, the researchers randomly selected 200 patients who marked their 
forms and another via NLP 200 who did not complete forms. All patients were at 
least 18 years old. They found the overall positive agreement for chest pain was 
.74, dyspnoea was .76 and for cough was .63. In their discussion they noted they 
did not possess sufficient data to determine if any discordance between 
symptom reporting by patients and clinicians has any significant clinical 
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consequences. Cohen’s kappa is a measurement of interrater reliability, the 
degree of agreement between raters that takes into account chance agreement 
(24). Cohen’s kappa for chest pain was 0.52, dyspnoea 0.46 and for cough it was 
0.38. They did point out their finding indicated what they called “substantial 
discordance” between patient reporting and care provider documentation on the 
symptoms (64).  As far as their limitations were concerned, they note the 
generalizability of the study depends on availability of electronic medical 
records, something that is becoming more common in the USA. The level of 
literacy or proficiency in English were potential variables to consider. 
Demographic characteristics may also be important.  
4.2.2 Shafiq et al 
Shafiq et al reported on patient and physician discordance in reporting of angina 
among stable coronary artery disease patients (66). Their cohort was 1257 
outpatients with coronary artery disease in 25 cardiology outpatient practices. 
The patients completed the SAQ just before their visit. One domain, for angina 
frequency categorized their angina over the last four weeks as none, 
daily/weekly or monthly. Following the outpatient visit, cardiologists then 
estimated the frequency of their patients’ angina. Shafiq et al pointed out one of 
the primary goals of treating patients is to optimize patients’ quality of life. This 
does require the physician to understand and report the presence and frequency 
of angina. This, they say, is challenging. They state that understanding the 
accuracy of physicians’ assessments of patients’ angina is a crucial step in 
improving angina recognition and treatment. They stated that if there was a low 
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correlation between patients’ and physicians’ assessment of the patients’ angina 
this would support efforts to include PROMs in clinical care.   
The study used the angina frequency score which they state correlated well with 
daily diaries of angina. The domain score is scaled between 0 and 100, a higher 
score indicating less angina. They created three groups, daily/weekly (score ≤60), 
monthly (score 61 to 99) and no angina (score = 100). Immediately following an 
outpatient visit the clinician completed a case report form to indicate whether 
the patient had experienced any chest pain within the last four weeks while 
being blinded to the patients’ SAQ scores. In a secondary analysis the study 
reported on whether cardiologist estimated, or patient reported angina 
correlated better with health-related quality of life. The quality of life scale of the 
SAQ was used along with the VAS of the EQ-5D. The reason for this secondary 
analysis was to assess whether the patient reported, or cardiologist estimated 
angina correlated more closely with the patient reported quality of life score. 
After the outpatient visit the results showed that 67% of patients reported no 
angina over the previous four weeks, 25% reported monthly angina and 8% 
daily/weekly symptoms. The cardiologists’ estimates for the same patients were 
76%, 7% and 17% respectively.  
There was a moderately strong association between the patients’ reports of 
angina frequency and their health-related quality of life. However, the 
association with physicians’ estimates were weaker. When patients reported 
having monthly angina cardiologists estimated that 46% of patients did not have 
any chest pain in the month. In cases where patients did report daily or weekly 
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angina, 26% were reported by their cardiologist to have no angina. The authors 
state they found a “significant discordance” between patients’ reports of angina 
frequency and their cardiologists’ estimate of the patients’ symptom frequency. 
The authors state that even when American Medical Association Physicians 
Consortium for Performance Improvement and the National Quality Forum 
endorsed the SAQ as a performance measure it was not adopted in clinical 
practice (67). The authors found “modest agreement” between patient reported 
and cardiologist estimated angina frequency with a Cohen’s kappa of 0.48.  
This study only examined angina frequency. When patients reported no angina, 
their cardiologist agreed 93% of the time. In those patients who reported either 
daily or weekly angina, 26% of their cardiologists noted no angina.   
4.2.3 Sewitch et al 
Sewitch et al reported on differences between patients’ and physicians’ health 
perceptions (68). They point out that  “ lower patient physician discordance is 
associated with positive health outcomes” (69). Another way to say this is that low 
discordance equals good agreement between patients and their physicians. They 
also state that comparing the findings of several studies is difficult for a number 
of reasons. These include discordance being based on different single items none 
of which are validated. Item scores may focus on different aspects of patient’s 
health or treatment. Finally, there is a lack of a clear definition of discordance.  
Their aim was to develop what they called “a psychometrically sound and 
comprehensive measure of patient physician discordance” (68). The population for 
the study were patients with inflammatory bowel disease (IBD). This was chosen 
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because IBD has an unpredictable course with remissions and exacerbations. The 
doctor patient relationship may influence outcomes (70). To develop a Patient 
Physician Discordance Scale (PPDS) they reviewed areas of discordance. The two 
strategies were to review empirical studies where agreement on a single item 
was discussed and to review agreement through statistics such as Cohen’s kappa 
which measures interrater reliability (24). Two domains were identified, relating to 
patient’s health status and to outpatient visits. Items were then selected for each 
domain. A gastroenterologist and a health psychologist were asked to select the 
top ten items. A consensus was then reached. The ten items were abdominal 
pain, disease activity, physical limitation, psychological distress, emotional well-
being, problem discussed, personal issues discussed, expectation of a 
prescription, expectation of testing and patient satisfaction.  
Each of the ten items was measured independently using a VAS. Following the 
outpatient visit, both the patient and their physician were given the PPDS and 
asked to rate their perceptions. The VAS rating was compared for each item. The 
authors concluded they had developed a “feasible” means of measuring patient 
physician discordance in patients with IBD. They noted that physicians were less 
perceptive than patients in assessment of psychological distress as opposed to 
pain or disease severity. Overall discordance was statistically higher for patients 
who started seeing their physician during the previous year. The authors 
hypothesized that this may be due to the developing relationship in the first 
year. The study lacked a “gold standard” measure for seven of the items in the 
scale. The authors also noted the lack of generalizability of the finding as only ten 
physicians were enrolled. The PPDS was however designed for a wide range of 
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chronic diseases. They commented that further measurements of patient 
physician discordance may impact adherence with medication and health 
services. 
4.3 Literature Review – Summary of 18 Articles 
A summary of the remaining eighteen articles identified in the literature search 
are in table 1. Discordance was a factor in fifteen of the eighteen publications 
(83%). The size of the cohort ranged between 30 and 12,043.  
In terms of statistical tests, T-tests, Chi squared and Cohen’s kappa were 
mentioned in two cases (11%). Univariate or multivariate regression was 
mentioned in four cases (22%). Fisher’s exact and Wilcoxon rank sum and Mann 
Whitney were each mentioned once.  
The PROM used varied but the most common was the VAS scale which was 
mentioned in 6 cases (33%). The Health Assessment Questionnaire was 
mentioned twice.  
The review below is split into two groups. The first are five articles most relevant 
to the theme of this thesis, namely patients’ quality of life. The remaining 
thirteen are less relevant but still worthy of comment. These are not in any order 
or priority or relevance.  
4.3.1 Brief details of five cases 
Barton et al (71) reported on patient physician discordance in assessments of 
global disease severity in rheumatoid arthritis. Their cohort was 223 patients. 
They concluded that nearly a third of patients differed from their physicians to a 
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meaningful degree in the assessment of disease severity. They also found the 
more depressed the patient the greater the discordance between patient and 
physician. 
Desthieux et al (2015) (72) examined discordance between patients and physicians 
in reporting of global assessment of disease activity in early spondyloarthritis. 
The assessment used a number scale from zero to ten. This was a French 
longitudinal multi-centre study with 702 patients at baseline. They used a linear 
mixed model. Both patients global assessment (PGA) and physician global 
assessment (PhGA) were compared. They point out that in rheumatoid arthritis 
(RA) patients assessments are based on a subjective perception of pain and 
functional incapacity, but PhGA focuses on inflammation. However, they state 
that in axial spondyloarthritis little is known about patient physician discordance. 
Using a ten-point scale, discordance was defined as a binary variable of ≥3 
points. Three groups were identified, PGA < PhGA, PGA = PhGA and PGA > PhGA. 
They found that the absolute mean PGA values were always higher than the 
mean PhGA values. At baseline 71.2% of patients had a global rating within two 
points of their physicians’ rating. Over time they found that the frequency of 
discordance was stable. 
Dobkin et al (73) examined discordance between patients and physicians in 
fibromyalgia. Their cohort was 182 women. The authors used the Patient-
Physician Discordance Scale (PPDS). The PPDS was a questionnaire developed by 
the authors in the context of a study of patients with inflammatory bowel 
disease. The PPDS is a VAS consisting of ten items derived from literature on 
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physician-patient agreement. The items relate to functioning, expectations of the 
outpatient visit, communication and patient satisfaction with the visit. The 
authors pointed out that with fibromyalgia patients often presented with vague 
non-specific symptoms such as body pain and stiffness in the morning. This lends 
itself to discordance between patients and their physicians. They used Principal 
Component Analysis. They found that the highest discordance was on 
satisfaction with the office visit where physicians systematically underestimated 
patients levels of satisfaction. They concluded there was a gap between what 
patients and their physicians experience during the clinic visit. 
Douglas et al (23) reported on patient physician discordance in goals of care for 
patients with advanced cancer. Their cohort was 378 patients. They concluded 
that there was significant oncologist-patient discordance relating to goals of 
care. They felt the early use of a VAS would inform the oncologist about the 
patients’ goals and aid the delivery of care.  
Henderson et al (74) reported on health related quality of life in early prostate 
cancer and patient and physician reporting of symptoms. This was a review of 
published studies. The purpose was to review quality of life questionnaires and 
make recommendations for future trials. For health-related quality of life three 
PROMs were reviewed, the short form 36, Short Form 12 and Short Form 8 as 
these cover several domains such as physical, general health and mental health. 
The authors stated that as therapies themselves may produce symptoms, future 
studies should include a general health related quality of life questionnaire. 
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4.3.2 Remaining Thirteen Articles 
De Maio et al (75) examined agreement between the patient and physician in 
symptomatic toxicity in anticancer treatment. Their cohort was 1090 patients, 
and they concluded that toxicities were at high risk of under reporting by 
physicians. They strongly supported the inclusion of patient reported outcomes 
into toxicity reporting in clinical trials.  
Thomas et al (76) examined patient and physician agreement on abdominal pain 
severity and the need for opioid analgesia. Their cohort was thirty patients. They 
concluded physicians underrate patients’ abdominal pain severity as assessed by 
VAS but are just as likely as patients to perceive that opioid analgesia is 
warranted. They reported “moderate agreement between physicians and 
patients on the dichotomous query: does the abdominal pain warrant opioid 
analgesia”.  
Tory et al (77) reported on patient physician discordance in disease assessment in 
juvenile dermatomyositis. Their cohort was 639 patients. They concluded that 
discordance was common and that this highlighted the importance of integrating 
patient reported outcomes into clinical practice and research.  
Jacome et al (78) reported on patient physician discordance in the assessment of 
adherence to inhaled asthma controller medication. Their cohort was 395 
patients. They found discordance in half of cases.  
Desthieux et al 2016 (79) performed a meta-analysis involving 11,879 patients 
suffering from rheumatoid arthritis. The purpose was to discover the drivers of 
patient-physician discordance. Discordance was based on ≥3 points on a 10-point 
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scale of PGA and PhGA. They found the percentage of patients with discordance 
was 43%. PGA was usually higher than PhGA and the main drivers were pain and 
functional incapacity.    
Sewitch et al (80) reported on patient physician discordance in inflammatory 
bowel disease with a cohort of 200 patients. They used a ten-item questionnaire. 
They concluded that greater physician awareness of distressed patients difficulty 
in processing clinically relevant information could lead to improved patient-
doctor communication.  
Ghukasyan et al (81) reported on patient and physician discordance in axial 
spondyloarthritis. Their cohort was 50 patients and they used a PROM called 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Their analysis used 
interclass coefficient. They concluded their outcomes could prompt the scientific 
community to revise outcomes or provide clear recommendations on how to 
collect outcomes.  
Fourrier-Reglat et al (82) reported on discordance between physician and patients 
of previous medical history in use of Non-steroidal anti-inflammatory drugs 
(NSAIDs). A  concern was patients reporting diseases that prescribers seemed 
unaware of in the patients’ past medical history. The cohort of 26,618 patients 
from the CADEUS study and they used a prescriber questionnaire and 
multivariate analysis. Their conclusions were that a substantial proportion of 
prescribers seemed unaware of the presence of risk-related past medical 
histories that the patient reported when asked.  
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Tago et al (83) reported on rheumatoid arthritis and the discordance between 
patients and physicians using a novel joint index. This was a study carried out in 
Japan. The cohort was 12,043 adults. This cohort was held in a national database 
called ‘NinJa’. Multivariate logistic and linear regression models were used. They 
found the number and distribution of affected joints influenced the perception 
of disease activity by patients and their physicians.  
Wang et al 2019 (84) reported on patient physician discordance in patients with 
psoriatic arthritis in a multi-ethnic Asian population in Singapore. The cohort was 
142 patients and the authors used generalised linear regression and univariable 
analysis. The PROM used was the Short Form 36. They concluded that increased 
age, higher fatigue levels, higher pain score and poorer mental health may 
explain underestimation of disease activity by physicians.   
Wang et al 2018 (85) also reported a year earlier on factors associated with 
patient-physician discordance. The cohort was 298 patients with ankylosing 
spondylitis in two tertiary centres in Singapore. They used the Bath Ankylosing 
Spondylitis Functional Index (BASFI). Several factors were found to be associated 
with patient physician discordance. These included BASFI scores, biological 
factors and  level of education. They concluded that global pain scores, lower 
educational level and what they called “current biologics” were associated with 
greater patient/physician discordance.  
Desthieux et al 2017 (86) reported on the determinants of patient physician 
discordance in global assessments of psoriatic arthritis. The cohort was 460 
patients and they used a zero to ten numeric scale. Discordance was a difference 
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of ≥3 points. Univariate and multivariable linear regression was used. 
Approximately a third of cases showed a discordance and discordance was more 
common in patients in remission. The authors concluded more work is needed 
on the patient perspective regarding disease activity. 
Sonnenberg (87) reported on in a personal view on patient physician discordance 
about risks and benefits in gastroenterology decision making. He presented two 
scenarios and used threshold analysis to produce different results depending on 
values assigned to identical medical events. He reported that safety and therapy 
are the two references that determine patient and physician utility functions. 
The author stated that gastroenterologists are more concerned with safety and 
prepared to spend more healthcare resources on safety because the occurrence 
of complications will affect their professional status. The author stated patients 
may receive less medical therapy in exchange for more procedural safety.  
Following a more recent literature review  I also identified the CADENCE study 
(88). This examined angina frequency in 2031 patients attending 207 Australian 
Primary Care physicians. Patients completed the SAQ detailing angina in five 
domains (frequency, recent change of symptoms, physical limitations, quality of 
life and satisfaction with current treatment). GPs completed the CCS and were 
asked if the patient’s angina was ‘optimally controlled’. The angina frequency 
domain of the SAQ was compared with GPs CCS. The primary endpoint was 
prevalence of weekly angina which was found in 29% of the cohort. There was a 
“close relationship” between the frequency of angina and patients’ perceptions 
of their quality of life assessed by the SAQ physical limitation and quality of life 
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scores. There was a discordance between GPs and patients’ assessment of 
angina control. The GPs reported 61% of patients had minimal angina-related 
impediment in physical activity, equivalent to the CCS class I. This included 12% 
of patients who reported daily angina.  GPs also considered patients’ angina to 
be optimally controlled in 80% of cases. The study concluded that physicians 
often underestimated the extent of angina and its impact on patients’ health 
status.  Physicians reported angina as being optimally controlled even in subjects 
reporting frequent symptoms. I would argue patients may confuse any 
non-cardiac chest pain with angina, thus overstating the prevalence of angina 
assessed by patients.  
4.4 Data  
The details of the Stent or Surgery Trial was discussed in chapter 2. The design 
paper was published in 1999 (89) and the main results in the Lancet in 2002 (90).  
Angina symptoms were reported in terms of CCS class, by clinicians, at baseline 
and again at 6- and 12-months follow-up (see Table 3).   Angina rating was 
performed in the context of a face-to-face visit, by clinical staff trained for this 
role as part of their trial responsibilities.  The descriptors of the CCS scale were 
presented in the trial CRF as explanatory notes – presented on the facing page of 
relevant section of the document.  Patients - at the same time-points - 
completed a number of PROM instruments including the Cardiac Health Profile 
(CHP) which includes the CCS question (40).  The CHP form also included the same 
descriptors of the CCS scale but translated into the local language.  
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This affords a unique opportunity to compare patient and clinician reporting of 
angina both before and after revascularisation.  
4.5 Statistical Analysis and Methods 
This chapter reports on a post-hoc analysis of data from the SoS trial. All analyses 
were performed using SPSS v 24, except for the weighted linear kappa tests 
which were performed using the tool at Vasser statistics site (91). Continuous data 
have been reported as means and standard deviations or medians and inter-
quartile range as appropriate.  Comparative tests were two-sided and a p value 
of ≤ 0.05 was assumed to indicate significance. All analyses have been performed 
on an intention to treat basis.  
Trial subjects were dichotomised into angina free (CCS = 0) or not. This was 
compared with McNemar’s test.  I calculated the 95% confidence interval for the 
magnitude of the difference both at baseline and at follow up. 
The magnitude and direction of any difference between individual pairs of 
observations was quantified by subtracting the patient score from the clinician 
score.  Descriptive statistics are presented as frequency histograms and the 
calculation of the mean score and standard error of the mean.  The values were 
compared using a Wilcoxon signed-rank test. 
I examined the rates of additional revascularisation in the year after symptom 
reporting - calculating the confidence intervals with the method of Clopper and 
Pearson and comparing the rate between groups using Fishers exact text. 
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4.6 Results 
The main results of the SoS trial have been published (90). Table 2 reproduces the 
baseline characteristics of the population, typical for revascularisation studies.  
There is a predominance of males and the mean age is just over 60 years.  There 
were no important differences between the randomised groups. 
 
Table 2 Baseline characteristics of patients randomised in the Stent or Surgery trial  
* n = 398 at baseline, ꝉ n = 373 at baseline 
 
Figure 1, below, describes the trial conduct and patient numbers at baseline and 
follow-up.  I present specific information on the number of individual CCS 
observations made by the clinician, by patients and the resulting number of 
paired observations at each time point and for the trial groups created at 
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randomisation.  There were 912, 886 and 887 sets of paired observations at 
baseline, 6 months and 12 months respectively. 
P a g e  71 
 
 
Figure 1 Patient Flow Diagram for Comparison of CCS Score by Patient and Clinician  
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Table 3 shows the number and proportion of subjects, at each time point, 
reported as manifesting each of the 5 possible CCS grades, with results for all 
recorded observations; for cases with paired clinician and patient information at 
that time point and, for these paired data, the information for the randomised 
treatment groups.  From these data we can make some key observations.  
Clinician reporting is more complete than patient reporting.  Our use of paired 
data does not result in substantial data loss, excluding about 6.5% and 7.6% of 
the clinician reported population at baseline and 12 months, respectively.  The 
CCS group proportions are consistent between the individual clinician or patient 
reported and paired data sets, suggesting that the paired data information is 
representative of the whole study population.    
Similarly, for all groups, a near identical distribution of proportions is seen at the 
6- and 12-month follow-up points.  Analyses at follow up were performed with 
the 12-month data but numerical results and conclusions would be 
representative of the findings at the earlier time point. 
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Table 3 Proportion of subjects for each CCS grade as reported by patients 
and clinicians at baseline and follow -up  
 
The proportion of subjects reported as being free from angina are summarised at 
Figure 2.  The p-values are derived from McNemar’s test. Physicians were 
reluctant to report freedom from angina at baseline, declaring CCS 0 in a single 
patient (1/912 = 0.01%).  In contrast 70/912 = 7.7% of patients reported this 
status - Difference (95%CI) = 7.6% (5.8 – 9.3); p = < .001. At follow-up, the 
reverse was true with clinicians declaring 639/887 = 70.1% to be free of angina 
compared to 449/887 = 50.6% of patients - Difference (95%CI) = -21.4% (-17.1 - -
25.8); p = < .001. Figure 2 also shows the separation of the confidence intervals 
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for the differences and confirms a substantial and significant change in the 
pattern of reporting from baseline to follow-up. 
 
Figure 2 Difference and associated 95% CI for subjects reported as angina -free by 
Clinicians and Patients at baseline and at 12 Months  
 
4.6.1 Differences between clinician and patient gradings 
Figure 3 shows frequency histograms for the difference in paired scores (clinician 
minus patient scores).  At baseline there is agreement in just over a third of cases 
(36%).  The linear weighted kappa statistic for overall agreement is 0.185.  
Cohen’s kappa is discussed in detail in chapter 1, section 1.4.1. The distribution 
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of the observed differences is near normal suggesting a tendency of the clinicians 
to report more angina (38% of cases) rather than less (26% of cases). 
 
Figure 3 Baseline and 12 Months Clinician Minus Patient CCS Score, Paired Data  
 
 
At follow-up, the distribution is very different. There is a greater proportion of 
paired values declaring the same grade (56% of cases).  The weighted kappa for 
overall agreement is 0.312.  The majority with discordant reporting now involves 
the clinician suggesting less angina rather than more (36% v 8% of cases).   
I compared the distribution of the individual differences in the paired value 
reporting at baseline and 12 months using Wilcoxon Sign Rank test and found 
this difference to be significant p = <.001. 
4.6.2 Subgroup analyses: Impact of Allocation, Patient Sex and Age 
Figure 4, Figure 5 and Figure 6 show histograms relating to  subgroup analyses 
for the treatment allocated at randomisation, patient sex and age, dichotomised 
at 65 years.  The nature and magnitude of the differences between clinician and 
patient reporting is consistent across these subgroups. 
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Figure 4 Baseline and 12M Clinician minus patient CCS – by allocation, Paired data  
 
 
Figure 5 Baseline and 12 mth Clinician minus patient CCS, split by pt sex, Paired data  
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Figure 6 B-line and 12M Clinician -pt CCS, age, dichotomised at 65 yrs, Paired data  
 
4.6.3 The impact of discordant symptom reporting on clinical outcome 
I was interested if discordant reporting of angina at 12 months affected mortality 
and repeat revascularisation over the subsequent 12 months. Table 4 summarises 
the results.  There are too few deaths to compare mortality between the groups.  
There were more additional revascularisation events, but the absolute numbers 
are modest and the associated confidence intervals are wide.  I note however 
that, when clinicians report more angina at 12 months, the rate of 
revascularisation over the subsequent 12 months is higher than for trial subjects 
with concordant reporting: 7.04% versus 2%; P = 0.036.  
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Table 4 Clinical events between 12 and 24 months in patients with concordant and 
discordant reporting of angina by clinicians and patients  
 
4.7 Discussion 
It was notable that the literature review in this chapter only identified twenty-
one results. However, I was not able to identify a single publication comparing 
CCS scores reported by patients and assessed by clinicians. The review identified 
comparisons and discordance in diverse disease groups such as rheumatoid 
arthritis, cancer, NSAIDS and inflammatory bowel disease. Shafiq et al (66) did 
report on discordance of reporting angina pain between patients and physicians. 
However, their instrument was the SAQ, not CCS.   
The results of my analysis of CCS scores suggest important differences in the 
reporting of angina by clinicians and patients, particularly when considered in 
relation to the timing of the observation - before and after revascularisation.  At 
baseline there is reasonable agreement with a modest over-statement of angina 
by clinicians.  At follow-up this is reversed with clinicians declaring a greater 
treatment effect than their patients.  These findings have clear and important 
implications for our perception of previous research in this field which has, in the 
main, focussed on clinician reporting.  
Angina Reporting at 12 Months Mortality
Angina Reporting Group n n (%) n (%) %  (95%CI) P Value
Agreement Between Clinician and Patient 499 5 (1%) 10 (2%) 2%  (0.097 - 3.65)
Clinician Reports More Angina 71 0 (0%) 5 (7.04%) 7.04%  (2.33 - 15.67) 0.036
Patient Reports More Angina 317 2 (0.63%) 10 (3.15%) 3.15%  (1.52 - 5.72) 0.36
Revascularisation
The 95% CI has been calculated by the exact method of Clopper and Pearson.
The P values are from Fishers exact test comparing each of the groups with discordant reporting, with the concordant group 
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The CCS was first described in the literature in 1976 (40) and is a classification of 
symptom burden and has been used to evaluate patients angina burden (Table 
5). CCS provides distinct grades, from one – the lowest - to four, describing the 
level of exertion that will induce angina. A grade zero is used to indicate no 
angina symptoms. CCS has been adopted worldwide (92). 
 
 
Table 5 Canadian Cardiovascular Society grading of angina pectoris  
 
I am not aware of any publications that compared clinicians’ assessment of 
patients’ angina burden with the patient’s own assessment using the CCS 
instrument.   
As detailed in the literature review, there are multiple instances of discordance 
between patients and physicians in reporting the patients’ health related quality 
of life. A number of authors recommended the use of PROMs in clinical care. 
Pakhomov et al (64) found substantial discordance between patients and 
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physicians but were unclear if this had any effect on clinical outcomes. Shafiq et 
al (66) found low correlation between patients and physicians of the patients 
angina and they stated this supports the use of PROMs in clinical care. Sewitch et 
al (68) looked at perceptions in healthcare. They found physicians were less 
perceptive about psychological distress than of pain or the severity of the 
disease. Douglas et al (23) felt early use of a VAS would help to inform the 
oncologist about patient goals and aid the delivery of care. Tory et al (77) 
highlighted the importance of integrating PROMs into clinical practice and 
research. Sewitch et al (80) concluded greater physician awareness of distressed 
patients could lead to improved patient-doctor communication.  
In the SoS trial, one inclusion criterion demanded angina symptoms and hence 
clinicians would be reluctant to declare CCS 0 as this would be a protocol 
violation.  It is also possible that patients with symptoms at screening had been 
prescribed additional medical therapy that had taken effect before functional 
status was reported.  Indeed, it is common for patients to have been prescribed 
medication for the relief of angina pain prior to a revascularisation procedure.  
At follow-up patients may report persisting chest discomfort or related 
symptoms (such as breathlessness) as angina even if the characteristics of the 
symptoms appear to have a non-cardiac cause when assessed by the clinician.  
This may suggest a role for more objective evaluation, with exercise testing for 
symptoms and imaging evaluation for ischaemia.  A recent study by Stone et al 
used formal adjudication for symptom reporting and, interestingly reported 
anginal rates comparable to those noted in SoS (93). 
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Clinicians may wish to be positive about the results of revascularisation and this 
may influence their reporting of angina symptoms resulting in a subconscious 
minimisation of the true symptom burden. Bias has been defined by Gludd as 
systematic errors that encourage one outcome over others (94). In the SoS trial 
only a small proportion of the population were randomised. This could lead to 
selection bias if the ‘healthier’ patients were approach for consent. Blinding in 
the SoS trial was not possible due to the nature of the interventions, that is, 
either CABG or PCI. Blinding refers to participants such as patients, health-care 
providers and others being unaware of the random allocation (94).  
Other potential sources of bias are more subtle. These can include cultural 
stereotyping of social groups, such as blacks or women (95).  Implicit bias is 
without conscious awareness and may impact clinical decision making and 
perpetuate health inequalities (95).  
The nature of the consultation process may be suboptimal in terms of setting, 
time available or in the communication process such that the clinicians do not 
acquire an accurate perception of the true symptom state. Fischer and Ereaut 
explored five main themes around the patient clinician consultation (96). These 
were making sense of the consultation itself; fear in the dynamic; invisible 
structures interfering with the consultation; the fragmented nature of 
conversations and the system itself. If the purpose of the consultation is not clear 
to both parties this can lead to a sub-optimal exchange.  Fischer and Ereaut 
suggest that fear is a significant element in the consultation, from both the 
patient and clinician. The patient may worry about the diagnosis or not 
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mentioning their symptoms in part or at all. The clinician may fear missing a 
diagnosis or may be anxious about the interaction itself. Invisible structures 
relates to the way a clinician has a mind map of how the consultation should 
evolve. There is limited time and many patients, but the patient is unaware of 
the clinician’s mind map. The invisible structures extend to the needs of the 
health administrators and other healthcare professionals. Everyone has their 
own idea about the ‘system’ works. Fragmented conversations refers to the 
hidden rules we all learn and employ in day-to-day conversation, such as taking 
turns. However, patient-clinician consultations are special cases with a different 
set of rules. One issue is that the patient may have several consultations over a 
year and may see this as one continuous exchange. However, the clinician may 
see hundreds of patient over the same time period and cannot reasonably be 
expected to recall the exact stage of each. Finally, system dynamics refers to the 
way a system evolved and can adapt. Fischer and Ereaut (96) suggest the quality 
of the consultation is reduced by the way the system has evolved and ability to 
innovate. Evolution has been bound up in the protected doctor and 
disempowered patient.  
4.8 Limitations  
These data are derived from a study conducted about 20 years ago and I cannot 
be sure that the results would translate to contemporary practice.  The specific 
setting of a clinical trial may have affected reporting as, for example, clinicians - 
keen to recruit for the study - may have been inclined to report symptoms as this 
was an inclusion criterion. 
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The SoS trial did not involve any protocol directed, symptom-limited exercise 
testing or other objective tests for ischaemia.  This made it difficult to identify 
the aetiology of chest discomfort reported at follow-up. 
The analyses are restricted to trial subjects with angina reporting by both 
clinicians and patient, resulting in the exclusion of some of the randomised 
population.  It is reassuring however that the requirement for pairing excluded 
only about 7% of the original population and that the distribution of reported 
CCS grades are very similar in the original and study datasets.   Patient retention 
over the 12-month follow-up period was good with 16 patients dying and a 
further 16 lost to follow-up. 
This study uses the CCS classification and limitations of this system have been 
identified in the literature (97, 98). There are only 4 grades for the description of 
symptoms and a single grade may describe different types of limitation with an 
assumption of equivalence. There is only a weak relationship between the scale 
and anatomic disease or prognosis.  I am not aware of any studies that have 
validated the use of the CCS grading system by patients and I cannot be sure that 
there will have been a consistent understanding of the explanatory text used in 
the presentation.  
Mortality and revascularisation data was available to me as detailed in Table 4. 
However, I did not have access to broader morbidity data by random allocation. 
With full access to more detailed patient data a more nuanced analysis would 
have been possible.  
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4.9 Conclusions 
The SOS trial was one of the first to report angina status by clinicians and 
patients in the same terms, both before and after coronary revascularisation. 
The results suggest that, when compared to patient reporting, clinicians may 
declare a modest overstatement of angina at baseline. In contrast, at follow-up, 
clinicians report a greater proportion of patients to be angina-free and tend to 
minimise the extent of symptoms in other subjects.   
It is possible that studies reporting outcomes declared by clinicians may 
exaggerate the therapeutic effect as perceived by patients. This may happen if 
the clinicians fail to correctly estimate the effect of the intervention on the 
patients’ quality of life. It may also be the case that patients overestimate the 
effectiveness of an intervention on their quality of life. Patients may be focused 
more on  functional improvement rather than preventing clinical deterioration.  
This chapter emphasises the importance of including patient reported outcomes 
in evaluating the treatment of coronary artery disease. 
 The next chapter examines the correlation between the VAS score and each 
domain of the SAQ.  
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 SAQ and EQ-5D VAS comparison 
As part of the data collection process for the SoS trial, participants were asked to 
complete several PROM instruments. These included the SAQ, a disease specific 
PROM and the EQ-5D, a generic PROM. These instruments were completed at 
three time-points: baseline, six and twelve-months post randomisation. In this 
chapter, results from two PROMs will be compared to identify the consistency of 
scores. The first question is to what extent is there correlation between the 
individual domains of the SAQ and the EQ-5D VAS score. Baseline and twelve 
months data will be analysed as previous work has shown that there is little 
difference between six and twelve-months (63). A second question is to what 
extent the instruments agree in reporting the direction and magnitude of change 
from baseline to follow-up at 12 months.  
5.1 SAQ Domains 
The SAQ measures both physical and emotional effects of ischaemic heart 
disease (or angina) over the previous four weeks (8).  There are five domains and 
nineteen questions. The five domains are physical limitation (PL) with nine 
questions; angina stability (AS) with one question; angina frequency (AF) with 
two questions; treatment satisfaction (TS) with four questions and quality of life 
(QL) with three questions. The angina frequency domain was included as this was 
considered both a critical measure of angina classification and also a prognostic 
indicator (30). Treatment satisfaction was included as the responses to this 
question may influence the therapeutic strategy. The response to each question 
is assigned an ordinal value and each domain score is summed separately and 
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converted into a score between zero and a hundred. Higher scores indicate 
better function. To achieve this, I subtracted the lowest possible score from the 
actual score. I then divided by the range and multiplied by one-hundred (30). I 
repeated this process for each domain.  
The patient burden in completing the SAQ is low and the measure can take 
between five and ten minutes to complete (8). Spertus et al suggest a change in 
score over time of ten points represented a change perceptible to patients and 
this was considered a clinically important difference in scores (30). 
5.2 Method for Scoring EQ-5D  
The EQ-5D used in the SoS trial has five dimensions of perceived problems for 
the respondent to answer. The five dimensions relate to mobility, self-care, usual 
activities, pain/ discomfort and anxiety / depression (41). The EQ-5D used by the 
SoS trial contained three possible answers for each dimension. These range from 
level 1, “I have no problems…”  to level 3, “I have extreme problems with…”. A 
‘one’ is the lowest score and three the highest. The response pattern for each 
questionnaire can, therefore, be expressed as five numbers. These range from 
11111 for the best possible health state or 33333 for the worst.  The EQ-5D can 
be used to calculate QALYs.  To achieve this, the five digits representing the 
health states need to be converted into a single summary number, or index 
value. The index values are generated by using a ‘Crosswalk Index Value 
Calculator’ which is obtained from the EuroQol group (https://euroqol.org/). The 
calculator applies weights derived separately from several countries, including 
the United Kingdom (UK).  
P a g e  87 
 
Following completion of the five dimensions the respondent is asked to complete 
a VAS.  This is a vertical scale in the form of a ‘ruler’. The scale is from zero at the 
bottom to one-hundred at the top. The respondent is asked to place an ‘X’ at the 
point on the scale which represents how they rate their health on that day. The 
EQ-5D reporting recommendations are that both the score derived from the five 
questions and the VAS are reported. There is no calculation of any correlation 
between the two scores.  The VAS represents just the respondents’ view of their 
health at that moment in time.  
There are two reasons why I decided not to use the index value as a comparison 
against the individual SAQ domain scores. The crosswalk index value calculator is 
based on a specific country and the SoS trial was international in scope. 
Approximately a third of all randomised patients were residents of the UK. At the 
time, the crosswalk index calculator I used did not have values for nine countries 
participating in the SoS trial. This amounted to 415 randomised patients at 
baseline from a total of 988 (42%). Omitting these countries data could have 
introduced bias.  
The second reason why I decided to not use the index value is related to the first. 
In general, the EQ-5D is calibrated for utility / cost analysis. The index value is 
based on a country average rather than being ‘person specific’. The index value 
for a patient represents how ‘good’ or ‘bad’ the health state is according to the 
preferences of the general population of a country. Therefore, the index value 
for a patient is “changed” to some extent and reflects the values of a country. As 
the SAQ domain score is based on the patients’ responses, I wanted to compare 
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this to the VAS which is asking the individual patient how they feel at that 
moment in time.  
5.3 Mean Imputation of Missing Data 
When the EQ-5D data was examined, there were twenty-four cases at baseline 
(Figure 7) and sixteen at twelve-months (Figure 8) where only four of the five 
domains were answered. This represents 2.71% rate of imputation at baseline 
from 886 cases where there was a date of completion of the EQ-5D and 1.76% 
imputation at twelve-months.  In these cases, I decided to impute the value by 
mean substitution, calculating the mean of the other four values and rounding 
this to a whole number.  
 
Figure 7 Details of 24 imputed values for EQ-5D at baseline 
BL = baseline, Q1 = Question 1 
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Figure 8 Details of 16 imputed values for EQ-5D at 12 months 
M12 = Month twelve, Q1 = Question 1 
 
Rombach et al (99) examined multiple imputation for PROMs. They found that 
imputation at item or overall score level provided similar results with sample 
sizes greater than five hundred. Simons et al (100) examined imputation to deal 
with missing EQ-5D data. They also found sample size to be important, with little 
difference in results with less than 500 records and missing data of between 5 
and 10%. They found index imputation to be more accurate with sample sizes of 
over five hundred.  
The SAQ data also contained missing values for each domain. Missing values 
were identified and dealt with separately for each domain using mean 
substitution. Mean substitution is recommended if there is a response to at least 
51% of the questions in a domain (101).  Only three of the five domains contained 
three or more questions, allowing mean substitution. In the physical limitation 
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domain, imputation was used in cases where there were up to four fields with no 
data for the time-point. In the domains of treatment satisfaction and disease 
perception only cases with one question where data was missing used mean 
substitution. The details of the number of records and the count of cases where 
mean substitution was used at baseline and twelve-months are detailed in Table 
6. 
 
Table 6 SAQ count of respondents and imputed values across two time -points  
 
5.4 Method of calculating differences between VAS and SAQ domains score 
The SoS database was accessed and a query created to extract data relating to 
both the EQ-5D VAS and the SAQ domains. This data was in relation to baseline 
and twelve-months. The query was output as an Excel spreadsheet. The columns 
were time point, VAS and five columns relating to the individual SAQ domains. I 
then created five more columns relating to the VAS minus the individual domain 
score.  
The second question concerning the sensitivity to change required another 
spreadsheet. This contained columns for VAS and each domain score at baseline 
and twelve-months on the same row for each patient. A column was created for 
the VAS at twelve-months minus the baseline VAS. Similar columns were then 
created for each SAQ domain score. It was then possible to import this into SPSS. 
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As you would expect the patients’ quality of life to improve after 
revascularisation the value for change should be a plus figure in most cases.  
5.5 Statistical Tests 
The data was analysed in SPSS v 26 in August 2020. I examined the relationship 
between the scores from the different SAQ domains and the EQ-5D VAS as 
reported by the same patient at simultaneous time points. Frequency histograms 
were created for the VAS and SAQ domains at baseline and again at 
twelve-months. I also report the number of cases, mean and standard deviation. 
Interquartile range (IQR) is reported for each of the SAQ domains and VAS. 
Scatter plots were created which included the correlation coefficient and the 
regression equation for the best fit line. Five Bland Altman plots, one for each 
SAQ domain, are created for baseline and another five for twelve-months. For 
the test of sensitivity to change from baseline to twelve-months, Wilcoxon rank 
sum was used to compare the VAS change to each separate SAQ domain change.  
5.6 Statistics 
The VAS score at baseline is a range between 0 and 100. Table 7 only displays the 
VAS scores at baseline and twelve-months that are divisible by 5, for example, 5 
or 10 etc. At baseline, of a population of 819 cases, 80% are divisible by 5 and 
57% divisible by 10. At twelve-months the figures for a population of 860 were 
73% and 48% respectively. All the baseline VAS scores between 0 and 50 that 
were not divisible by 5 amounted to 69 cases, or 8% of the population. This 
demonstrates a propensity for respondents to select a rounded figure relating to 
their VAS score (102). The same issue did not occur for the SAQ, as shown in Table 
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8. Jain et al  (103) found that people find non round numbers unique and jarring. 
Jain et al stated (103) “Numbers have a language and give non-numerical 
perceptions”. The authors also went on to say there was no apparent reason for 
this kind of behaviour.  
 
 
Table 7 Visual Analogue Scores Baseline and 12 -months grouped into divisible by 5 









Table 8 Physical Limitation Baseline and 12 -months grouped into divisible 
by 5 and 10  
 
Table 9 is baseline and twelve-month descriptive statistics for mean, standard 
deviation and IQR for each of the SAQ domains and the VAS score. The 
numerator is shown for each domain. Both the VAS and individual SAQ domain 
scores range was between zero and one hundred.  
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With the exception of QL, all IQR’s were either the same or lower at twelve-
months than at baseline. The QL IQR increased from 25 to 33 at twelve-months 
indicating a slightly greater spread of scores.   
 
Table 9 Baseline and 12-month comparison between VAS and SAQ 
domains 
n = numerator, PL = physical limitation, AS = angina stability, AF = angina frequency,  
TS = treatment satisfaction, QL = quality of life, IQR = interquartile range 
 
5.7 Baseline Histograms 
Baseline histograms were created for VAS (Figure 9), PL (Figure 10), AS (Figure 11), 
AF (Figure 12), TS (Figure 13) and QL (Figure 14).  
 




Figure 10 Baseline histogram: Physical Limitation  
Numerator = 815, Mean = 48.06, Standard deviation = 20.14, Interquartile range = 29 
 
 
Figure 9 Baseline histogram: Visual Analogue Scale  
Numerator = 819, Mean = 57.79, Standard deviation = 19.96, Interquartile range = 30 
P a g e  96 
 
 
Figure 11 Baseline Histogram: Angina Severity  
Numerator = 787, Mean = 46.25, Standard deviation = 31.58, Interquartile range = 50 
 
 
Figure 12 Baseline Histogram: Angina Frequency  
Numerator = 782, Mean = 54.42, Standard deviation = 27.74, Interquartile range = 50 
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Figure 13 Baseline Histogram: Treatment Satisfaction  
Numerator = 801, Mean = 81.78, Standard deviation = 14.10, Interquartile range = 18 
 
 
Figure 14 Baseline Histogram: Quality of Life  
Numerator = 809, Mean = 38.65, Standard deviation = 20.46, Interquartile range = 25 
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5.8 Twelve-Month Histograms 
Twelve-month histograms were created for VAS (Figure 15), PL (Figure 16), AS 
(Figure 17), AF (Figure 18), TS (Figure 19) and QL (Figure 20). 
 
Figure 15 Twelve-months Histogram: Visual Analogue Scale  














Figure 16 Twelve-months Histogram: Physical Limitation 
Numerator = 855, Mean = 63.83, Standard deviation = 18.05, Interquartile range = 29 
 
 
Figure 17 Twelve-months Histogram: Angina Stability  
Numerator = 770, Mean = 80.42, Standard deviation = 26.66, Interquartile range = 50 
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Figure 18 Twelve-months Histogram: Angina Frequency  
Numerator = 833, Mean = 88.47, Standard deviation = 18.92, Interquartile range = 20 
 
 
Figure 19 Twelve-months Histogram: Treatment Satisfaction  
Numerator = 828, Mean = 87.47, Standard deviation = 13.72, Interquartile range = 33 
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Figure 20 Twelve-months Histogram: Quality of Life  
Numerator = 832, Mean = 71.91, Standard deviation = 21.84, Interquartile range = 33 
 
5.9 Magnitude of Change Baseline to Twelve Months 
Histograms were also created to display the magnitude of change by subtracting 
the baseline from twelve-months data.   
5.9.1 Magnitude of Change - VAS 
Figure 21 relates to the Visual Analogue Scale. The numerator was 722 and the 
mean is 16.95, indicating a positive change over the year. However, the standard 
deviation is 21.49. 
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Figure 21 Magnitude of Change Over 12 Months: Visual Analogue Scale  
Mean = 16.95, Standard Deviation = 21.49, Numerator = 722 
 
5.9.2 Magnitude of Change – Physical Limitation 
Figure 22 relates to Physical Limitation. The numerator here is 877 and the mean 
is 16, indicating a positive change over the year. There is a wide standard 
deviation of 22.1.  
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5.9.3 Magnitude of Change – Angina Stability 
Figure 23 relates to angina stability. The numerator is 764 and the mean is 35.5 
indicating more stable angina over the year. However, the standard deviation 








Figure 22 Magnitude of Change Over 12 Months: Physical Limitation  
Mean = 16, Standard Deviation = 22.104, Numerator = 877 
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5.9.4 Magnitude of Change – Angina Frequency 
Figure 24 relates to angina frequency. The numerator is 812 and the mean is 
33.63, an improvement over the twelve-months. Again, there is a wide standard 
deviation of 29.  
 
 
Figure 23 Magnitude of Change Over 12 Months: Angina Stability  
Mean = 35.50, Standard Deviation = 37.992, Numerator = 764 
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5.9.5 Magnitude of Change – Treatment Satisfaction 
Figure 25 relates to treatment satisfaction. The numerator is 834 and mean is 
5.56. Although there is an improvement in treatment satisfaction it is modest. 









Figure 24 Magnitude of Change Over 12 Months: Angina Frequency  
Mean = 33.63, Standard Deviation = 29.071, Numerator = 812 
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5.9.6 Magnitude of Change –Quality of Life 
Figure 26 relates to quality of life. The numerator is 846 and the mean is 34. The 







Figure 25 Magnitude of Change Over 12 Months:  Treatment Satisfaction  
Mean = 5.56, Standard Deviation = 16.036, Numerator = 834 
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Figure 26 Magnitude of Change Over 12 Months:  Quality of Life  
Mean = 34.07, Standard Deviation = 224.86, Numerator = 846 
 
5.10 Bland and Altman Plots 
Bland and Altman plots were created to compare the differences between the 
VAS and each domain score of the SAQ with the averages of the two reported 
scores. Bland and Altman plots do not say if agreement is sufficient or if one or 
the other method of scoring should be used. It simply quantifies the bias and 
range of agreement between the measures (104).  
To create these plots in SPSS I first needed to create two additional variables for 
each domain of the SAQ.  One was the difference between the VAS and each 
domain of the SAQ and the other was the average of the two reported scores.  
To calculate the upper confidence interval (CI), I used the formula (Std Dev x 
1.96) + mean. The lower confidence interval was calculated using the formula: 
Mean - (Std Dev x 1.96).  
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I then created the plots in SPSS which start as a scatter plot. The ‘Y’ axis was the 
difference between the two variables and the ‘X’ axis the mean of the two 
variables. In the chart editor I then added three lines using the ‘Y-axis reference 
line’ tool. I then entered the value for the mean calculated in Excel. I repeated 
this process for the upper and lower CI limit lines.  
5.11 Scatter Plots 
A scatter plot will show the relationship between two variables and how strongly 
the two variables are related. However, a high correlation does not imply there is 
good agreement between the two variables. Correlation is concerned with the 
strength of a relationship, not the agreement between them (104). 
For clarity, the various Bland and Altman and scatter plots will be described  as 
they relate separately for each domain of the SAQ. The descriptions will include 
baseline and twelve-months. Both the magnitude of change and the extent of 
agreement will be described.  
5.12  VAS and Physical Limitation 
5.12.1 Bland Altman 
Bland and Altman proposed a method of measuring the agreement between two 
measurements or raters by measuring the mean differences (104). This differs 
from correlation, which measures how strongly two measures are related, not 
their differences. High levels of correlation do not imply good agreement. On a 
Bland and Altman plot, the Y axis represents the difference between two 
measures and the X axis represents the mean average of the two measurements. 
A Bland and Altman plot does not state if the agreement is suitable to use one or 
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the other measures. The plots also contain a central line indicating the mean and 
an upper and lower 95% confidence interval line.  
Figure 27 is the Bland Altman plot displaying baseline data. The mean is 9.82 
indicating a bias towards VAS and the majority of data points fall between the 
upper and lower CI. However, the CI’s are wide, between 52 and -33. There is a 
wide spread of data points on the ‘x’ axis from 0 to 90 which you would expect at 
baseline prior to revascularisation.  
Figure 28 is the twelve-month Bland Altman plot. The mean is 10.46 so the bias 
favouring VAS has increased and again there are wide CI’s at 46 to -25, although 
the CI’s are not as wide as baseline. The majority of the data points are above 60 
on the ‘x’ axis. This would be expected as twelve-months after revascularisation 
the physical limitations should not be worse than at baseline. 
 
 
Figure 27 Bland Altman Plot Baseline: VAS and Physical Limitation  
Mean = 9.82, Upper 95% CI is 52, Lower 95% CI is -33 
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Figure 28 Bland Altman plot twelve-months: VAS and Physical Limitation  
Mean = 10.46, Upper 95% CI = 46, Lower 95% CI = -25 
 
5.12.2 Scatter Plots 
Figure 29 is the scatter plot for VAS and PL at baseline. The data range of both 
axis is wide from 0 to 100. The correlation coefficient is 0.167, showing a weak 
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Figure 30 is the twelve-month data. This shows a slightly stronger correlation 
coefficient of 0.213. Data points are more common above 60.  
 
 
Figure 29 Scatter plot baseline: VAS and Physical Limitation  
Correlation coefficient = 0.167 
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Figure 30 Scatter plot twelve-months: VAS and Physical Limitation  
Correlation coefficient = 0.213 
 
Figure 31 is a scatter plot displaying the magnitude of change over 
twelve-months. Although there is still a low correlation coefficient of 0.124, the 
majority of data points are clumped together centrally.  
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Figure 31 Change from baseline to 12 months: VAS and Physical Limitation  
Correlation coefficient = 0.124 
 
5.13 VAS and Angina Stability 
5.13.1 Bland Altman 
Figure 32 displays baseline data. The mean is 11.47 indicating a bias towards VAS 
but there are very wide 95% confidence intervals of between 72 and -49. There is 
a very wide range of data points on the mean axis.  
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Figure 32 Bland Altman plot baseline: VAS and Angina Stability  
Mean = 11.47, Upper 95% CI is 72, Lower 95% CI is -49 
 
Figure 33 for twelve months shows a negative mean of -7.16, a bias in favour of 
AS which is a reversal of the baseline position and the 95% CI’s are lower at 43 to 
-57. 
P a g e  115 
 
 
Figure 33 Bland Altman plot twelve-months: VAS and Angina Stability  
Mean = -7.16, Upper 95% CI = 43, Lower 95% CI = -57 
 
5.13.2 Scatter Plots 
Figure 34 is the baseline scatter plot for VAS and AS. There is a weak correlation 
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Figure 35 relates to twelve-months and shows a similar weak correlation 
coefficient of 0.142.  
 
Figure 34 Scatter plot baseline: VAS and Angina Stability  
Correlation coefficient = 0.115 
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Figure 35 Scatter plot twelve-months: VAS and Angina Stability  
Correlation coefficient = 0.142 
 
Figure 36 is the magnitude of change over twelve-months. Again, there is a very 
weak correlation coefficient of 0.086 indicating almost no relationship between 
VAS and AS in terms of the magnitude of change. 
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Figure 36 Change from baseline to 12 months: VAS and Angina Stability  
Correlation coefficient = 0.086 
 
5.14  VAS and Angina Frequency 
5.14.1 Bland Altman 
Figure 37 is the Bland Altman for baseline. The mean is 3.24 indicating a small bias 
in favour of VAS. There are very wide confidence intervals of 59 to -52 and the 
data points range from 0 to 100 on the ‘x’ axis.  
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Figure 37 Bland Altman plot baseline: VAS and Angina Frequency  
Mean = 3.24, Upper 95% CI is 59, Lower 95% CI is -52 
 
Figure 38 is the twelve-month plot and shows a mean of -14.03 indicating a bias in 
the opposite direction from baseline, now in favour of AF. The 95% CI are slightly 
narrower.  
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Figure 38 Bland Altman plot twelve-months: VAS and Angina Frequency  
Mean = -14.03, Upper 95% CI = 23, Lower 95% CI = -51 
 
5.14.2 Scatter Plots 
Figure 39 is the baseline scatter plot and the correlation coefficient is 0.108 
indication a poor relationship between VAS and AF.  
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Figure 39 Scatter plot baseline: VAS and An gina Frequency 
Correlation coefficient = 0.108 
 
Figure 40 relates to twelve-months and shows a similar picture with a correlation 
coefficient of 0.181.  
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Figure 40 Scatter plot twelve-months: VAS and Angina Frequency  
Correlation coefficient = 0.181 
 
Figure 41 is the magnitude of change over twelve-months, and it also shows a 
poor correlation coefficient of 0.105.  
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Figure 41 Change from baseline to 12 months: VAS and Angina Frequency 
Correlation coefficient = 0.105 
 
5.15 VAS and Treatment Satisfaction 
5.15.1 Bland Altman 
Figure 42 is the baseline plot. It shows a negative mean of -23.85 indicating a bias 
towards TS. The majority of data points on the ‘x’ axis are above 60 and the CI’s 
are very wide.  
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Figure 42 Bland Altman plot baseline: VAS and Treatment Satisfaction  
Mean = -23.85, Upper 95% CI is 19, Lower 95% CI is -67 
 
Figure 43 relates to twelve-months and again the mean is a negative -13.23 and a 
narrower 95% CI than baseline.  
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Figure 43 Bland Altman plot twelve-months: VAS and Treatment Satisfaction 
Mean = -13.23, Upper 95% CI = 18, Lower 95% CI = -45 
 
5.15.2 Scatter Plots 
Figure 44 relates to baseline VAS and TS. The correlation coefficient is only 0.043. 
There are a number of extreme outliers, such as VAS = 50, TS = 0 and VAS = 0 and 
TS = 100.  
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Figure 44 Scatter plot baseline: VAS and Treatment satisfaction 
Correlation coefficient = 0.043 
 
 
Figure 45 is at twelve-months and shows a slightly improved correlation 
coefficient of 0.203.  
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Figure 45 Scatter plot twelve-months: VAS and Treatment Satisfaction  
Correlation coefficient = 0.203 
 
Figure 46 is the magnitude of change from baseline to twelve-months comparing 
VAS with TS. The correlation coefficient is 0.03 indicating almost no relationship 
between the two axes.  
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Figure 46 Change from baseline to 12 months: VAS and Treatment Satisfaction  
Correlation coefficient = 0.034 
 
5.16 VAS and Quality of Life 
5.16.1 Bland Altman 
Figure 47 is the baseline plot and the mean is 19.3 indicating a bias towards VAS. 
There is a wide 95% CI of 60 to -21.  
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Figure 47 Bland Altman plot baseline: VAS and Quality of Life  
Mean = 19.3, Upper 95% CI is 60, Lower 95% CI is -21 
 
Figure 48 is for twelve-months, and the mean is now 2.28, so only a slight bias 
towards VAS. The 95% CI has shifted to 42 to -37.  
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Figure 48 Bland Altman plot twelve-months: VAS and Quality of Life 
Mean = 2.28, Upper 95% CI = 42, Lower 95% CI = -37 
 
5.16.2 Scatter Plots 
Figure 49 is baseline VAS and QL. There is a wide range of data points with a 
correlation coefficient of 0.229.  
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Figure 49 Scatter plot baseline: VAS and Quality of Life  
Correlation coefficient = 0.229 
 
Figure 50 shows an almost identical twelve-month correlation coefficient of 
0.232.  
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Figure 50 Scatter plot twelve-months: VAS and Quality of Life  
Correlation coefficient = 0.232 
 
Figure 51 is the magnitude of change from baseline to twelve-months comparing 
VAS with QL. The correlation coefficient is 0.144, a very poor relationship 
between the two axes.  
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Figure 51 Change from baseline to 12 months: VAS and Quality of Life  
Correlation coefficient = 0.144 
 
5.17 Discussion 
In the SoS trial, patients completed both the SAQ and EQ-5D. This created a 
unique opportunity to compare results from both instruments. As can be seen 
from the results above there is very poor relationship between the VAS and each 
domain of the SAQ.  
 The comparison in this chapter was undertaken to answer two fundamental 
questions. To what extent are the results at baseline and twelve-months similar? 
Secondly, how do the instruments compare in their ability to measure change 
from baseline to follow-up?  
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The Bland Altman plots relate to the VAS score minus each individual domain 
score at baseline. The plots were repeated using data from twelve-months. The 
confidence interval in the plots represents the 95% confidence around the mean. 
As can be seen for baseline figure 27 and figure 47, in every case the confidence 
intervals are wide.  As for the sample size, the average numerator for the plots at 
baseline was 799 and at twelve-month it was 824. The take-away message from 
the Bland and Altman plots is there is a poor relationship between the two 
variables. The same is true of the scatter plots.  
In a review of PROMs by Mackintosh et al in a report to the Department of 
Health in 2010, the recommendation for a disease specific instrument for angina 
was to use the SAQ. The rationale was that the SAQ had the most evidence 
supporting its use for patients undergoing CABG or PCI. The one drawback 
mentioned was the SAQ was developed for cardiac disease in general, not 
cardiac surgery (8).  It was stated that psychological well-being is a predictor of 
recovery and that a procedure such as CABG may have long-term effects on 
cognitive functioning. The SAQ does not include cognitive functioning questions.  
5.18 Reasons for Discordance 
There could be a number of explanations for the differences between the scores 
of VAS and SAQ domains. The first is that SAQ is a disease specific instrument 
and the other, EQ-5D is a generic instrument used in many different conditions 
and populations. They were developed with different intentions and, therefore, 
could not be expected to record identical elements of quality of life. The EQ-5D 
can be used in any population group. It can be used to calculate 
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cost-effectiveness or in a range of clinical trials in diverse disease populations. It 
can be used in healthy populations and between populations with different 
diseases (41). It only contains five questions and a VAS. The SAQ by comparison 
was developed to quantify the physical and emotional aspects of coronary artery 
disease (30). The SAQ contains nineteen questions in five domains.  
There is still a discrepancy in what the patient is reporting between the SAQ and 
VAS. This is that the SAQ asks about how the patient felt over the previous four 
weeks. This means for the SAQ the patient has to consider their average in 
response to each question as opposed to how they feel when they complete the 
questionnaire. The VAS asks how the patient feels at that moment in time.  
Another possible explanation for discordance is the effect of round number  
preference (102) affecting the VAS score but not the SAQ domain scores. This 
effect is seen in table 7 where, at baseline, 80% or the 819 respondents picked a 
VAS score that was divisible by 5. By contrast, table 8 shows that for the PL score 
only 11% of 815 respondents score was divisible by 5.   
5.19 Administration of PROM  
The method of administration of the PROMs may influence the results recorded 
by patients. Mercieca-Bebber et al (105) researched this, and found several issues 
in the way trial coordinators saw their role in the use of patient recorded 
outcomes. They refer to trial coordinators as either clinical research coordinator, 
site coordinator or research nurse. These staff are responsible for providing 
instructions to the participant in how to complete the questionnaire or PROM. 
This person also deals with enquiries from participants and may also enter data 
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into electronic systems such as a trial database. It is not known if each site 
participating in the SoS trial were given a Standard Operating Procedure (SOP) 
relating to the administration of the multiple PROMs. The authors state that 
although the type of PROM will be stated in trial protocols, details covering the 
method of administration are not often included. Although the same member of 
staff will give the same PROM to each patient, there may be subtle differences 
between multiple sites. In some sites, a member of staff may sit with the 
participant helping them to complete the PROM and answering questions. In 
another site a different approach may be taken where the member of staff 
leaves the room and lets the participant complete the PROM by themselves. The 
absence of a fully detailed standard method of PROM administration for every 
site may influence the results. However, it could be argued that as this was a 
randomised trial, any effects would be the same in each arm. 
Research staff such as nurses and clinicians are very busy and can be involved 
with multiple studies simultaneously. This can have the effect of ensuring the 
PROM is completed in a standard way at the correct time-point a low priority. 
There are competing pressures which may contribute to the allocation of a 
limited time to the PROM. These can include managing trial governance, 
consenting participants, reporting adverse events, encouraging Principal 
Investigators to complete required paperwork, organising meetings and patient 
appointments, collecting specimens, managing budgets, liaising with sponsors 
and preparing ethics applications. 
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In amongst these varied duties, administration of a PROM may not be a high 
priority. Mercieca-Bebber et al (105) found that 85% of trial staff stated that 
patient reported outcome tasks formed a minor part of their role. Other issues 
identified included the organisational skills of trial staff, the level of empathy and 
rapport with participants, checking questionnaires for completeness and 
following up missing data and how to deal with data that was concerning in its 
nature. A significant challenge was balancing the needs of the patient with the 
needs of the trial. This was especially the case with participants who were very 
unwell or deteriorating when trial staff felt a flexible approach to data collection 
was warranted.  Trial staff reported challenges with interpretation of the 
wording on questionnaires. The authors reported trial staff saying questions 
frequently missed by participants reflected a poorly worded question. 
Participants could challenge the need to answer a question that they felt was 
unrelated to their condition. The authors concluded that trial staff are at the 
heart of patient reported outcome data and their role is of the upmost 
importance. Further education was needed to ensure staff understand the 
impact of PROM administration.  
With the SoS trial whatever shortcomings there may have been concerning how 
the PROM instruments were administered, the same issues would apply for 
patients allocated to each arm of the trial and between participating sites. This 
suggests there is something intrinsic about the PROMs themselves that accounts 
for the lack of correlation in scores.  
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5.20 Mode of Administration of PROMs 
Bowling in 2005 (106) researched how the mode of questionnaire administration 
impacted the results. Modes of questionnaire delivery include person-to-person, 
participant completion alone in a clinical setting, postal delivery of 
questionnaires, electronic collection via website, telephone keypad or iPad etc. 
There are many influences on how participants may respond depending on the 
mode of administration. Thus, it can be difficult to separate out the effects of the 
mode of delivery on the results. Bowling states there are four steps involved in 
answering questionnaires which involve cognitive demands. These are 
understanding the question, recalling the information from memory, evaluating 
the link between the retrieved information and the question and finally 
communicating the response. The author states the most burdensome mode is 
likely to be self-administration as this demands the respondents are literate, do 
not have visual impairments and have dexterity of wrist and fingers. 
Respondents need the ability to tick boxes, to read and recognise numbers and 
write accurately and be able to follow instructions. The author also commented 
that the concept of “data quality” is a vague and there is no agreed “gold 
standard”. It could be response rates, “accuracy” of responses (not defined) or 
absence of bias.  
Non-measurement error was mentioned by Bowling as a potential reason for 
misleading results. This concerns the participants who are not included in a trial 
and how this may influence the results. The population chosen needs to be 
representative and from an up-to-date list. There can be sample selection bias 
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but in the SoS trial selection was limited by the trial protocol and participants 
who were eligible completed the same PROM instruments.  
5.21 Influence of the Setting in PROM Completion  
Bowling also states cultural, social and language may not have the same meaning 
to participants in questionnaires. The actual interaction can vary between 
settings, sessions and the member of staff conducting the collection process. 
Tourangeau et al (107) suggested a more subtle factor may be the pace of the 
interaction.  
5.22 Conclusions 
As seen from the results of the comparison between VAS scores and individual 
SAQ domains at both baseline and twelve-months, there is a very weak 
relationship. It is not, therefore, possible to recommend one or the other.  Each 
instrument, the VAS and SAQ, is designed for a different purpose. The EQ-5D is 
calibrated for utility / cost analysis and can be used for many conditions and 
diverse populations. It is generic. By contrast, the SAQ is disease specific and 
aimed at patients with angina. It is designed to reflect the nuances of the quality 
of life for this patient population. The choice of instrument for a trial, therefore, 
depends on what outcomes are measured. If a primary outcome is a cost analysis 
then the EQ-5D is the obvious choice. If the outcome includes quality of life, then 
the SAQ is the instrument. There is nothing to stop both being used, other than 
an increased burden on the participant who will be required to complete both. 
Any researcher using both PROMs will need to be aware of the lack of 
P a g e  140 
 
relationship between the two, either at a single time point or in terms of the 
magnitude of change.   
The next chapter will examine if the same results can be obtained by comparing 
the full nineteen question SAQ with a shortened, seven question version. 
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 Validation of full SAQ with 7 question version 
In this chapter I  present an external validation of a truncated instrument - SAQ-7 
- with data from the SoS trial using data recorded before and after 
revascularisation by CABG or PCI. The rationale for a shorter version of the SAQ is 
to make PROMs research easier, more practical, cheaper, more likely to be 
performed but without losing accuracy. 
6.1 Introduction 
The short form Seattle Angina Questionnaire (SAQ-7) has been designed to make 
research process more efficient, streamlined, acceptable, and cheaper to 
patients and researchers. 
The full SAQ is designed to examine limitation in patients’ quality of life and is, 
therefore, a disease specific PROM (30). It consists of nineteen questions in five 
domains. The domains group questions in physical limitation (PL), angina stability 
(AS), angina frequency (AF), treatment satisfaction (TS) and quality of life (QoL). 
Traditionally, patients are asked to complete the SAQ prior to an intervention 
and again at a fixed time post-procedure. The two could then be compared to 
quantify the change in the patients’ perception of their QoL.  The SAQ has been 
endorsed by both the American College of Cardiology (56) and reviewed by the 
Patient-Reported Outcome Measurement Group, Oxford for the Department of 
Health (8).  
There is strong support for the use of PROMs in clinical care but their use by 
clinicians in assessing their patient’s QoL is rare (108). One study found that none 
of the practices checked used the Kansas City Cardiomyopathy Questionnaire 
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(KCCQ) or another QoL measure and instead clinicians assessments of heart 
failure patients was the norm (108). One author pointed out that key barriers to 
the universal adoption of PROMs in clinical practice could be summarised as the 
vowels: PROMs must be Actionable, Efficient, Interpretable, Obligatory and User-
friendly. With this in mind, Chan et al developed a short version of the SAQ they 
called SAQ-7 (57). This consisted of just seven questions in three domains. These 
were physical limitation, angina frequency and quality of life. Although the 
individual domains were scored from zero to one hundred (with higher scores 
indicating better QoL), a single overall score could also be calculated.  This had 
the dual benefits of reducing the patient burden and providing clinicians and 
patients with a single score. The individual scores from SAQ-7 were compared to 
the SAQ and showed high levels of concordance (0.88 – 1.00). There was good 
construct validity, meaning SAQ-7 measured what it claimed to measure, and 
SAQ-7 was highly reproducible.  
6.2 Literature Review 
Details of the SAQ7 were first published in 2014 making a literature search less 
likely to return a high number of articles. The database used in the search was 
the Healthcare Database Advanced Search (HDAS). An iterative process was used 
which eventually returned four articles. The initial search was limited to “Seattle 
Angina Questionnaire” and “Seattle Angina Questionnaire Short Version”, title 
only. The search string failed to return the UK version of the SAQ. The next 
iteration was  ("Seattle Angina Questionnaire" AND ("short version" OR "SAQ7" 
OR comparison)), again title only. This returned three results but still not the UK 
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version. Therefore, the final iteration wording for the search string was “"Seattle 
Angina Questionnaire" and ("short version" or SAQ7 or SAQ-7 or SAQ-UK or 
comparison or compare).  The criteria were title only and limited to articles in 
English. This returned four articles. 
6.2.1 Garratt et al 
Garratt et al developed what they called a UK version of the SAQ (109). The 
authors rationale for the development of this United Kingdom version of the SAQ 
was to “anglicise” it and assess the measurement properties in patients with 
stable angina in the North of England. The instrument they developed was 
shorter than the original SAQ, having just fourteen questions. The assessment of 
the SAQ-UK was for reliability, validity and responsiveness. The authors reported 
that physiological measurements are poorly related to survival and health status. 
They point out the SAQ is one of the most widely used PROMs for angina 
patients but that it was validated using patients in the United States. The authors 
tested validity by comparing the SAQ-UK to the Sort Form SF-12 and EQ-5D. Data 
was collected in twelve general practices. There were 959 patients who received 
a questionnaire and of these, 655 (68%) took part in the study.  
To “anglicise” the SAQ the word “showering” was changed to “bathing or 
showering”. The phrase walking “more than one block” was changed to “walking 
more than one-hundred yards” and the word “bothersome” was changed to 
“troublesome”. As further evidence to justify producing a shorter version of a 
PROM the authors mention the Short Form 36. This is a thirty-six-question 
generic PROM. However, the original eight domains in two groups of mental and 
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physical health were reduced to twelve questions used in both the United 
Kingdom and United States. The authors used Principal Component Analysis 
(PCA) (110) to assess the dimensionality of the instrument. The SAQ scores were 
compared to SF-12 and EQ-5D. the authors concluded their study did 
demonstrate a strong support for their modification of the instrument in United 
Kingdom patients. They also demonstrated that the five items removed had high 
levels of missing data and were not contributing to one of the clinically 
meaningful dimensions demonstrated by PCA. Following a further literature 
search for “SAQ-UK” in Pubmed in August 2020, no further articles were 
identified. This suggests the modified instrument has not been used since its 
development.  
6.2.2 Chan et al 
Chan et al developed a short, seven question version of the full SAQ (57) called the 
SAQ7. The rationale behind developing the SAQ7 was stated to be the limited 
use of the full SAQ in routine clinical practice. This was said to be in part due to 
its length, at nineteen questions.  Chan et al used data from five longitudinal 
studies of coronary artery disease patients. This allowed data from 10,408 
patients to be included from three distinct patient groups. These were stable 
coronary artery disease, elective PCI and finally acute myocardial infarction. The 
SAQ is divided into five domains, and for the SAQ7 the authors used the three 
that directly measure patients current health status. These are physical 
limitation, angina frequency and quality of life. The goal was to match 
comparability between the SAQ7 and SAQ.  
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Chan et al selected three items from the original nine item physical limitation 
domain. Each of the three items represented a different level of intensity. The 
three items were walking indoors on level ground, limitation of gardening, 
vacuuming or carrying groceries and finally lifting or moving heavy objects. Both 
items from the SAQ angina frequency were retained. From the original SAQ 
quality of life scale two questions were retained. These were enjoyment of life 
and feelings about spending the rest of your life with symptoms as they are now. 
Construct validity was assessed using Kendall τ-b rank correlation coefficient. The 
results for construct validity showed that there was good agreement between 
the SAQ7 and SAQ scores. With reproducibility, patients assessed between five 
and six months after elective PCI the SAQ7 showed excellent values and mean 
changes were less than 1 point. One month after PCI the mean SAQ7 scores 
increased by at least 18 points. The authors suggested this showed excellent 
reproducibility. Clinical change was reflected in the responsiveness scores. The 
authors pointed out that despite the SAQ being developed over twenty years ago 
the SAQ is seldom used in routine clinical care. Development of a short, validated 
version was an attempt to address this issue. A second issue addressed by the 
SAQ7 was to create a single “summary score” that combines the three domains. 
This, the authors suggested, may allow clinicians to quickly screen patients for a 
significant change in their health status (57). 
6.2.3 Arnold et al 
Arnold et al compared the SAQ with a daily angina diary (111). Data was collected 
from 917 patients with stable angina and type II diabetes. The trial randomised 
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patients between placebo or ranolazine 1000mg twice a day. Trial subjects were 
given an electronic diary with built in prompts for daily entry. Subjects recorded 
angina episodes and use of sublingual medication. They also completed the SAQ 
at randomisation and again at eight weeks. In the analysis, patients were 
required to have taken the trial drug for at least 14 days and completed diary 
entries for at least 4 weeks. The SAQ angina frequency scores (SAQ-AF) were 
used in the comparison. The SAQ-AF frequencies were compared with the diary 
entries. The results were that there was a significant correlation between SAQ-AF 
and the diary entries of sublingual medication use. The authors suggested this 
was further support for the use of the SAQ in clinical trial of treatments designed 
to assess patients’ angina symptoms.  
The authors point out some limitations of the use of patient diaries. In studies 
using paper diaries, these can be completed inappropriately, for example by 
multiple entries in a single day. There can also be low compliance by patients. 
Electronic diaries are more reliable and have high rates of compliance. A 
downside is they are costly. Patients can still miss entering data for a day in an 
electronic diary. Electronic patient diaries are not practical in routine patient 
care. The authors also pointed out a limitation of the SAQ in comparison to daily 
diaries. This was that the SAQ asks about an average over the last four weeks. 
The SAQ also assumes that patients can in fact recall their angina status over the 
previous four weeks. The authors point out that “recall bias” is important with a 
symptom like angina which is episodic in nature. Recall bias is a tendency for 
selective memory of events from the past (112). However, the correlations 
between diary and SAQ data suggests patients recall is not biased.  
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6.2.4 Dougherty et al 
Dougherty et al compared three quality of life instruments (113). These were the 
SAQ, SF-36 and Quality of Life Index-Cardiac VIII. The authors’ rationale for the 
study was stated as coronary artery disease is often tackled for years before 
meaningful conclusions about quality of life are obtained. Medical care evolves 
over the years confounding the interpretation of outcomes. Quality of life 
measures provide a more responsive insight into health status. However, there 
are now multiple quality of life instruments available to be completed by 
patients. Three of these instruments were compared with the CCS classification 
to test reproducibility. Details about the Quality of Life Index can be found on 
this website https://qli.org.uic.edu/index.htm. The cohort was 107 patients.  
The authors found with test-retest calculations all three instruments were stable 
with repeated administration at baseline and two-weeks. The SAQ scales had a 
close relationship with functional status defined by the CCS. The SF-36 did not 
demonstrate such a close relationship with the CCS and the Quality of Life Index 
had the lowest correlation. The authors concluded that the SAQ was the most 
responsive to both angina status and clinical change for trials of angina. The 
authors did refer to CCS as the “gold standard”. However, it should be noted the 
CCS was designed to be completed by physicians after a discussion with their 
patients as an assessment of their patients’ angina burden. CCS is not routinely 
completed by patients.   
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6.3 Methods 
6.3.1 Comparing SAQ with SAQ-7 
I  decided to compare the SAQ with derived SAQ-7 using data from the Stent or 
Surgery Trial (SoS) (33). Trial participants were also required to complete several 
PROMs including the SAQ at baseline and again at six and twelve-months post 
randomisation. The method of scoring the SAQ and deriving a single summary 
score is described in detail below and was developed by Chan et al (57). Each 
domain was transposed to a score from zero to one hundred. A summary score - 
detailed below -  (SAQ-SS) was then derived by taking the average of three 
domains, PL, AF and QoL. My comparison uses both the SAQ-SS and a summary 
score derived from the short SAQ, the SAQ7-SS, also detailed below. 
6.3.2 Method of establishing a summary score (SAQ-SS) 
The full SAQ derives a score for each of the five domains. Chan et al derived a 
method of calculating a single overall score which incorporates elements of three 
domains: physical limitation, angina frequency and quality of life. These three 
domains were selected as Chan et al stated they directly measure patients’ 
current health status (57). Each domain is dealt with slightly differently. Neither 
the TS or AS domains were used in the SAQ-SS. 
6.3.2.1 Physical Limitation Score 
This is the most complex of the domain scores to calculate. An individual item 
score of ‘6’ is treated as missing. If five or more responses are missing, no score 
is computed; otherwise, missing responses are imputed as follows. Questions are 
grouped into three levels of exertional requirements. The lowest group includes 
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dressing, walking and showering (1a, 1b and 1c); the middle group includes 
climbing, gardening and walking more than a block (1d, 1e and 1f); the highest 
group includes running, lifting and sports (1g, 1h and 1i). Within each group, if 
one or two responses are missing, then assign each of them the average of the 
non-missing responses in that group. If all responses in the lowest or highest 
group are missing, then assign each of them the average of the middle-group 
responses. If all responses in the middle group are missing, then assign each of 
them the average of the means of the lowest and highest groups. The score is 
then calculated by taking the average of the nine responses and rescaling to 0-
100, as follows: 
𝑆𝐴𝑄 − 𝑃𝐿 = 100 ∗ [(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑞𝑢𝑒𝑠𝑡𝑖𝑜𝑛𝑠 1𝑎 − 1𝑖) − 1]/4 
6.3.2.2 Angina Stability Score 
This domain contains one question which can be scored from 1 to 6. A score of 
‘6’ is treated as ‘3’ for the purposes of scoring. If the response is missing no score 
is computed. The score is calculated by rescaling as follows: 
𝑆𝐴𝑄 − 𝐴𝑆 = 100 ∗ [(𝑄2) − 1]/4 
6.3.2.3 Angina Frequency Score 
The Angina Frequency score corresponds to questions 3 and 4. These can be 
scored between 1 and 6. In this domain an item score of  ‘6’ is included. If both 
questions are missing no score is computed. Otherwise the score is calculated by 
rescaling as follows: 
𝑆𝐴𝑄 − 𝐴𝐹 = 100 ∗ [(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑄3 𝑎𝑛𝑑 𝑄4) − 1]/5 
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6.3.2.4 Treatment Satisfaction Score 
The treatment satisfaction score corresponds to questions 5 to 8. Question 5 is 
treated differently to questions 6 to 8. Question 5 score of ‘6’ is treated as a ‘5’. 
If three or more responses are missing , no score is computed. The score is 
calculated by rescaling as follows: 
𝑆𝐴𝑄 − 𝑇𝑆 = 100 ∗ [(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑄5 𝑡𝑜 𝑄8) − 1]/4 
6.3.2.5 Quality of Life Score 
The quality of life score corresponds to questions 9 to 11. If two or more 
responses are missing, no score is computed. Otherwise, the score is calculated 
by taking the average of the non-missing responses and rescaling as follows: 
𝑆𝐴𝑄 − 𝑄𝐿 = 100 ∗ [(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑄9 𝑡𝑜 𝑄11) − 1]/4 
6.3.3 SAQ Summary Score 
The summary score integrates three domains into a single score. The domains 
are physical limitation, angina frequency and quality of life. If all three domain 
scores are missing, no summary score is computed. Otherwise, the summary 
score is calculated as the average of the non-missing domain scores as follows: 
𝑆𝐴𝑄 − 𝑆𝑆 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑆𝐴𝑄 − 𝑃𝐿, 𝑆𝐴𝑄 − 𝐴𝐹 𝑎𝑛𝑑 𝑆𝐴𝑄 − 𝑄𝐿 
6.4 Rationale for single summary score 
Chan et al used data from five longitudinal cohort studies to calculate a single 
summary score using three domains and seven questions (57). All 10,408 patients 
had coronary artery disease (CAD) and were in five multi-centre registries. The 
three types of CAD in the registries were stable CAD, elective PCI and acute 
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myocardial infarction (MI). With each clinical setting, Chan et al conducted a 
series of analyses to evaluate construct validity, reproducibility, responsiveness 
and predictive validity of the short seven question SAQ7 and did the same for the 
full nineteen question SAQ. The three items selected from the original nine-
question physical limitation domain represented low, moderate, and high-
intensity activity.  
6.5 Method of Calculating Short Form SAQ-7 
The PL uses three questions from the SAQ. These are 1b (walking indoors on level 
ground), 1e (gardening vacuuming or carrying heavy groceries) and 1h (lifting or 
moving heavy objects). The AF uses two questions, 3 (over the last 4 weeks, how 
many times have you had chest pain, chest tightness or angina) and 4 (over the 
last 4 weeks, on average, how many times have you had to take nitroqlycerin for 
your chest pain, chest tightness or angina). The QoL uses two of the three 
questions, question 9 (over the last 4 weeks, how much has your chest pain, 
chest tightness or angina interfered with your enjoyment of life) and 10 (if you 
had to spend the rest of your life with your chest pain, chest tightness or angina 
the way it is right now, how would you feel about this). Each of the three 
domains was transposed into a score ranging from zero to one hundred.  
6.5.1 SAQ7-Physical Limitation 
This is the most complex of the three domains used in the SAQ7-SS. For purposes 
of scoring, a response of 6 is coded as missing. If two or more responses are 
missing, no score is computed; otherwise, missing responses are imputed as 
follows. If the response to Question 1b or Question 1h is missing, it is assigned 
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the response from Question 1e. If the response to Question 1e is missing, it is 
assigned the average of the responses to Questions 1b and 1h. The score is then 
calculated by taking the average of the three responses and rescaling to 0-100, as 
follows: 
𝑆𝐴𝑄7 − 𝑃𝐿 = 100 ∗ [(𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑄1b, 1e and 1h)-1]/4 
6.5.2 SAQ7 Angina Frequency 
AF score relates to questions 2 and 3 in the SAQ. If both questions have no 
response, no score can be calculated. Otherwise the score is calculated by taking 
the average of the non-missing responses and rescaling to 100 as follows: 
𝑆𝐴𝑄7 − 𝐴𝐹 = 100 ∗ [(𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑄2 𝑎𝑛𝑑 𝑄3) − 1]/5 
6.5.3 SAQ7 Quality of Life 
This was originally referred to as ‘disease perception’ and uses two questions, Q9 
and Q10. If both questions have no response, no score can be calculated. 
Otherwise the score is calculated by taking the average of the non-missing 
responses and rescaling to 100 as follows: 
𝑆𝐴𝑄7 − 𝑄𝐿 = 100 ∗ [(𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑄9 𝑎𝑛𝑑 𝑄10) − 1]/4 
If all three summary scores are missing it is not possible to calculate the 
summary score for SAQ7. Otherwise, the SAQ7-SS is the average of the SAQ7-PL, 
SAQ7-AF and SAQ7-QL. The SAQ-SS could then be compared to the SAQ7-SS. 
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6.6 Results 
Statistical analyses were performed using SPSS v26. Data from all three time-
points – baseline, six and twelve-months was initially analysed separately and 
then combined. Scatter plots were created for each timepoint. 
6.6.1 SAQ and SAQSS – Scatter Plot, Baseline 
Figure 52 shows a strong, linear positive correlation with few outliers. The 
correlation coefficient was 0.957. The majority of the data points fall between a 
score of 20 and 80.  
 
Figure 52 Scatter plot of SAQ and SAQ-7 summary score for baseline 
Correlation coefficient = 0.957 
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6.6.2 SAQ and SAQSS – Scatter Plot, Six Months 
Figure 53 is a scatter plot for six-months. Again, there is a strong, linear 
correlation. However, the majority of the data points are greater than 60 and the 
correlation coefficient is 0.951.  
 
Figure 53 Scatter plot of SAQ and SAQ7 summary score for six-months 
Correlation coefficient = 0.951 
 
6.6.3 SAQ and SAQSS – Scatter Plot, Twelve-Months 
Figure 54 is the scatter plot for twelve-months data and shows a correlation 
coefficient of 0.951. Two scatter plots, for six and twelve-months, display a 
homoscedastic pattern, and the six and twelve-month plots are characteristically 
fish shaped.  
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Figure 54 Scatter plot of SAQ and SAQ7 summary score for twelve-months 
Correlation coefficient = 0.951 
 
6.6.4 SAQ and SAQSS – Scatter Plot, All Three Time-points 
Figure 55 combined all three time-points into a single scatter plot. The 
correlation coefficient is 0.97.  
P a g e  156 
 
 
Figure 55 Scatter plot of SAQ and SAQ-7 summary score, all time-points 
Correlation coefficient = 0.97 
 
6.6.5 SAQ and SAQSS – Scatter Plot, CABG Patients 
I also compared data relating to CABG and PCI but combining all time-points. 
Figure 56 is data relating to CABG patients and shows a correlation coefficient of 
0.967 and the majority of data points above 50. The numerator is 1365. 
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Figure 56 Scatter plot of SAQ and SAQ-7 summary score, CABG cases 
Correlation coefficient = 0.967 
 
6.6.6 SAQ and SAQSS – Scatter Plot, PCI Patients 
Figure 57, shows a correlation coefficient of 0.973. With all scatter plots, there 
was always a very strong positive correlation between SAQSS and SAQ7SS. The 
correlation coefficient never went below 0.951.  
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Figure 57 Scatter plot of SAQ and SAQ-7 summary score, PCI cases 
Correlation coefficient = 0.973 
 
6.6.7 SAQ and SAQSS – Bland Altman Mean Summary Score 
I created a Bland Altman plot of the mean summary score by both SAQ7SS and 
SAQSS using all data from three time-points. (Figure 58). Positive differences 
indicate the SAQSS is greater than the SAQ-7, and negative differences the 
reverse. Ninety-five percent of most observations are between plus or minus 8 of 
the mean when the total score is one hundred. The mean itself is -0.16. In the 
mid-range between twenty to eighty there is good agreement. At low scores 
there is a tendency for SAQ-SS to report lower values. In the lower range, below 
twenty there are five cases with a mean greater than 8.36 (0.12% of the total), 
meaning the SAQ-SS was higher than the SAQ7-SS. However, in the higher range, 
above eighty, there are twenty-five cases with negative scores with a mean less 
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than minus 8.68 (0.93% of the total) indicating the SAQ7-SS scores more than the 
SAQ-SS.  
 
Figure 58 Bland and Altman Plot of mean summary score 
95% CI = 8.36 to -8.68, mean = -0.16 
 
6.7 Discussion 
Outcome measures in studies examining the management of CAD have 
traditionally reported the incidence of adverse events such as mortality, or 
subsequent myocardial infarction or unplanned revascularisation. Important as 
these are, they tell us nothing about the patient’s views of the effect of the 
intervention on their quality of their life. This is important as only a small 
percentage of patients die or experience adverse events in any specific period (2).  
Even if used, physiological measurements do not directly correlate to health 
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status which is important to patients (109). PROMs were developed to focus on 
the patients ‘own assessment of their quality of life (QoL) and were routinely 
introduced into the National Health Service (NHS) in 2009 where they have an 
increasing role in clinical research(2). PROMs are self-administered questionnaires 
that seek to quantify patients’ symptoms, function and health-related quality of 
life (114). 
There are limitations to the SAQ. One is the number of questions the patient is 
required to answer. Another is the absence of a single overall score which would 
make the PROM easier for both patients and clinicians to interpret. Garratt et al 
developed an ‘anglicised’ and shorter version, they called SAQ-UK (109). The study 
used Principal Component Analysis and this resulted in five of the nineteen 
questions being removed from the questionnaire, leaving fourteen questions. 
These were grouped into three domains, Physical Limitation, Angina symptom 
and perception and finally treatment satisfaction. The SAQ-UK has been used in 
clinical trials (115) but no single, overall score can be calculated.  
The 2007 report “Our NHS Our Future” (7) recommended routinely recording 
outcomes assessed by patients themselves. This was followed in 2008 by a 
requirement in acute services to report PROMs for four surgical procedures (26). 
Since then PROMs have been collected for an ever-wider range of conditions and 
procedures. Some PROMs, such as the Short Form 36 contain thirty-six questions 
and are time-consuming for patients to complete. Others, such as the generic 
PROM EuroQol 5D are just five questions and are used widely. Two 
considerations for the more ubiquitous use of a PROM are the burden on 
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patients and the ease of interpretation by healthcare workers. The SAQ-7 meets 
both criteria with very high correlation between results from both SAQ-7 and 
SAQ.  
The CCS is a tool used by clinicians to assess patient’s angina burden. However, a 
recent study found discordance between clinicians and patients assessment of 
their angina burden when both used the CCS at the same timepoints (63). This 
highlighted the need to pay more attention to the patient’s assessment of their 
quality of life.  
Black points out that the adoption of PROMs in England is largely driven by 
government wishes for the public to compare healthcare providers performance 
(20). He also points out that there are three main challenges in implementing the 
widespread use of PROMs. These are minimising the time and cost of collection, 
analysis and presentation of data; achieving high rates of patient participation 
and thirdly, recognising the dimensions of quality, which are safety, effectiveness 
and experience (20). 
6.8  Limitations 
There are several limitations to this study. In creating a single summary score, we 
lose the discriminatory ability derived from specific domains. The SoS trial data is 
now over two decades old. It is conceivable that over that time-period patients’ 
expectations and responses to the SAQ may have evolved. I have tested the SAQ-
7 against a SAQ summary score that was itself ‘created’ by a methodology that 
may be flawed. The original SoS trial was limited to a cohort who were suitable 
for either PCI or CABG. This limited the population to a small percentage with 
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multi vessel disease. A further limitation was the reluctance of patients to 
consent to a random allocation of either PCI or CABG. The SoS trial authors 
speculated that only around 3-6% of patients undergoing multivessel 
revascularisation were in fact randomised (33). The SoS trial was open label, and 
as such both patients and clinicians would be aware of the allocation. Therefore, 
it is conceivable this may have influenced decisions about symptom reporting. 
The SAQ does not ask about shortness of breath as the desire was to focus on 
coronary heart disease. Shortness of breath is a common comorbidity in patients 
with angina (116) and has a significant impact on quality of life. 
6.9 Conclusions 
The SAQ-7 can be completed by patients using a single side of paper in less than 
one minute. A summary score can easily be calculated providing healthcare 
workers with a single number between zero and one hundred. This incorporates 
elements of physical limitation, angina frequency and quality of life.  
Chapter 7 examines the strengths and weaknesses of questionnaires.  
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 Questionnaires and Thesis Summary 
7.1 Questionnaires: Quantitative Versus Qualitative Methods 
Collating data collected in questionnaires uses a quantitative approach. Almalki 
(117) describes quantitative research as a “deductive approach” and that 
researchers regard the world as being outside of themselves. There is some 
“objective reality independent of any observations” (118). Quantitative research 
uses mathematically based models and statistics to test a hypothesis. The use of 
questionnaires such as PROMs in quantitative research has several advantages 
alongside limitations. My research uses quantitative data derived from 
questionnaires. As such, every participant answers the same questions with 
identical multiple-choice response options. The questions themselves are what 
the researchers think of as the most important aspects of the subject. This may 
differ from what participants think of as important. This could be said to be 
detached from the idiosyncrasies which make people who they are, the minutiae 
of people’s lives and their everyday reasons and explanations. It is beyond what 
LeCompte called “vignettes and thick description” (119). There is no place for the 
nuanced detail of patients’ perspectives in my thesis and I do not seek to claim 
this. The results from PROMs are simply aggregated into numbers. Quantitative 
and qualitative methods simply use a different lens to view the world. 
Quantitative may be considered a mile wide, qualitative is a mile deep. 
Quantitative data can be used to generalise about populations whereas 
qualitative research would not make this claim.  
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7.1.1 Advantages of Questionnaires  
7.1.1.1 Financial Considerations 
After paying for a licence to use a specific PROM, the PROM questionnaire itself 
can be used by a large number of respondents and, therefore, per respondent 
they are inexpensive. There is no requirement to hire specialist staff to deliver 
the PROM, it can be explained by existing research staff. The questionnaire could 
be available via a website or emailed to participants. 
7.1.1.2 Practicality 
A PROM can be targeted at a specific population and there is choice concerning 
the type of PROM which in turn dictates the type of questions involved. A PROM 
can be completed by large groups of a specific population in a short timeframe 
with minimum supervision or explanation. 
7.1.1.3 Speed 
A PROM can be a very quick way to obtain information about the participants. 
Researchers can avoid having to use any other organisation to deliver them and 
collect and collate results. It would be possible to collect information in a single 
day via a PROM completed online.  
7.1.1.4 Ability to Scale Up 
It is possible to scale up a questionnaire to include large numbers of 
respondents. It is possible to include a link to your website and this link could be 
in other specialised self-help websites. This link could invite responses from any 
or specified geographical regions. Questionnaires could be sent out by mass 
email  or data collected from a convenience sample via a kiosk.  
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7.1.1.5 Comparability 
A significant advantage of questionnaires is the ability to compare the summary 
of responses with other research using the same questionnaire. Alternatively, 
repeated questionnaires with the same population over time can be compared 
and statistically analysed.  
7.1.1.6 Anonymity 
A questionnaire completed and left in a local collection point may make the 
respondent feel anonymous, therefore potentially increasing completion rates. 
There is no way the investigator could contact the respondent to clarify a specific 
answer for example.  However, a counter argument was put forward by Lelkes et 
al (120). They argued that complete anonymity may in fact compromise accuracy. 
Complete anonymity reduces accountability. Their research found that 
completely anonymous questionnaires compromised accuracy rather than 
improving it. They referred to the process of “satisficing”, a bias towards 
selecting the first response offered or selecting a “Don’t know” option more 
often.  It should be noted that in the SoS trial each participant was assigned a 
unique Case Record Number (CRN) and would be known to the staff at each 
participating site. The trial administrators would only see the CRN number and 
would not know the identity of the participant. It is not known what method was 
used in administering the PROMs to the participants, such as in person or by 
post.  
7.1.1.7 Extensive Coverage of a Topic 
A questionnaire can be extensive asking a full range of questions on a subject. 
These questions can cover several domains, including physical, emotional and 
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practical. It would also be possible in an online questionnaire to use branching 
logic. This means that the following question depends on the respondent’s 
answer to the previous. This can lead to a great deal of details concerning one 
particular aspect of the respondent’s life.  
In summary of the advantages of questionnaires, they can be cheap, highly 
practical, fast, large scale, easy to compare to other questionnaires, anonymous 
and detailed.  
7.1.2 Disadvantages of Questionnaires 
Alongside the advantages of using questionnaires, there are disadvantages 
7.1.2.1 Fatigue 
O’Reilly-Shah (121) refers to respondent fatigue where respondents provide less 
thoughtful answers to questions in the later parts of a questionnaire. This can be 
caused by the length of the survey, the subject or the complexity of the 
questions such as the language used or if the question is open-ended or closed. A 
closed question may be “Did you attend university?” An open question might be 
“How do you feel about attending university?” This fatigue may lower the quality 
of the data or lead to an increase in unanswered questions.  
7.1.2.2 Dishonesty 
De Schrijver (122) pointed out that if a topic is of a sensitive nature, respondents 
may adopt one of three responses. The respondent may refuse to respond to the 
questionnaire at all, refuse to answer specific questions or answer questions 
dishonestly. Each will negatively influence data quality. Dishonest responses can 
be of two types. Desirable behaviour such as wearing a seat belt can be over 
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reported and undesirable behaviour such as drug use under reported. The author 
did state that classifying a question as “sensitive” was not straightforward.  There 
is the potential for social pressure to affect a participant when dealing directly 
with a doctor. There may be  a tendency for a participant to want to ‘please’ 
clinicians to avoid a ‘fuss’ by answering questions in a particular way.  
7.1.2.3 Interpretation 
Block (123) reported that in discussions, respondents often talked about issues 
raised in the questionnaire which yielded additional information which would 
not otherwise have been available to the researchers. The questionnaire 
represents a pre-conceived idea about the important aspects of a topic. 
However, when respondents talk about the topic, they raise issues not captured 
in the questionnaire. Interpretation is more difficult where a multiple-choice 
question is used. The respondent may have given a different answer had there 
been more choices available. Another problem is the interpretation of a scale 
giving a range of numbers. One person may respond with a six, and another a 
three, but this may mean the same to the individual respondents. However, 
analysis will treat the responses as different.  
7.2 Bias in Questionnaire 
The PROM most commented on in this thesis is the SAQ. This was evaluated for 
validity, responsiveness and reproducibility. However, the question of intrinsic 
bias invites discussion.  
Choi and Pak state bias is a “deviation of results or inferences from the truth, or 
processes leading to such a deviation” (124). They also state bias is a pervasive 
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problem in the design of questionnaires. They classify three main categories of 
bias. These are the way a question is written, the way the questionnaire is 
designed and the way the questionnaire is administered. Questions can be badly 
worded and ambiguous, too complex, too short, involve technical jargon or 
vague words. A scale on a questionnaire may be missing a “don’t know” option 
or there may be an overlapping interval. The authors also report bias as a result 
of the formatting of a question on a page, either vertically or horizontally. 
Central tendency bias occurs when a respondent selects the middle option from 
a list.  
In an online blog, Jovancic (125) points out four types of bias in questionnaires. 
These are sampling, non-response, response and question order bias. Jovancic  
states sampling bias occurs as a result of the way respondents are selected. 
Response bias can be in the form of acquiescence bias, where the respondent 
tends to agree with whatever is being stated. Another form of response bias is 
demand bias. This occurs when the respondent attempts to guess what is behind 
the questionnaire and then respond with what they believe are the correct 
answers. Desirability bias occurs when the respondent provides answers that 
reinforce characteristics that are seen as socially desirable. Another form of bias 
is non-response. Even if the questionnaire is sent to all the relevant members of 
a population this does not guarantee they will all respond. Question order bias is 
where the initial questions could influence the following answers given. When 
there are multiple-choice answers, the order of these answer options can 
influence the results.  
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7.3 Key Thesis Findings 
In chapter 4, I investigated discordance between clinician and patient on 
reporting QoL. I found no other references to both clinicians and patients 
reporting on the patients’ CCS grade. There were key differences in the findings. 
Before the revascularisation procedure, clinicians tended to slightly differ from 
patients and reported a higher angina burden. However, at twelve-months this 
was reversed with a greater difference. It is possible patients may be reporting 
any chest pain as angina. Clinicians will be in a better position to attribute the 
pain to non-cardiac causes. The key implication is that studies reporting 
outcomes using CCS assessed by clinicians may overstate the effectiveness of 
treatment.  
Chapter 5 examined the relationship between SAQ and EQ-5D  VAS scores. I 
found the scatter plots showed a very poor correlation coefficient and the 
magnitude of change over twelve-months also differed and showed a wide 
standard deviation. EQ-5D and SAQ are different PROMs created for two distinct 
purposes. The EQ-5D VAS asks the patient how they feel now, whereas the SAQ 
relates to the previous four weeks. As there is such poor correlation between 
VAS and SAQ it would not be advisable to rely on just one of the PROMs.  
Chapter 6 investigated if a shorter, seven question version of the SAQ would 
compare with the full SAQ. In each case a single summary score was created. 
Using a series of scatter plots I found the correlation coefficient was very high, 
typically above 0.95, almost a perfect correlation. However, it should be noted 
the summary score was created by a method that may contain flaws. Using just 
seven questions does lose some of the discriminatory ability of the full SAQ. 
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However, a short disease-specific PROM with a single summary score may 
improve the take-up of this instrument in day to day clinical practice and provide 
useful information for both clinicians and patients.  
Chapter 7 examined issues abound the use of questionnaires.  There are several 
advantages and disadvantages. Gathering large amounts of data from multiple 
patients will often involve a questionnaire. This occurs not just in the healthcare 
setting but in all walks of life. There will always be limitations and biases in the 
design, layout and population invited to participate. However, questionnaires 
remain a key element of PROMs. A greater understanding of their limitations and 
potential biases would be an advantage for any researcher.  
7.4 Routine Clinical Use of PROM Data 
Black (20) pointed out that routine use of PROMs is restricted to England, Sweden 
and some parts of  USA. One further observation by Black was that in England 
the use of PROMs data has been driven by government wishes for the public to 
compare their healthcare providers performance. It is substantive. However, in 
Sweden and the USA the medical profession has focused on improving clinical 
care of individual patients, a formative approach. This represents a fundamental 
difference in the use of PROMs data.  
If the fundamental aims of healthcare are to improve patients’ QoL then patients 
themselves are in the best position to report on this. As Black points out, 
patients do welcome being involved in decisions about their care and treatment. 
A response rate for a patient who only completes one questionnaire is likely to 
be higher than for a clinician who has to complete one for every patient. Asking a 
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clinician to assess their own practice may introduce observer bias. Observer bias 
is defined as “Systematic difference between a true value and the value actually 
observed due to observer variation” (126). Finally, ensuring patients’ views are at 
least considered in strategic decision making is likely to influence public 
accountability.  
Griggs et al (21) referred to PROMs as when maximised in clinical settings can “be 
leveraged to inform clinical decision making, to improve quality of care and to 
foster communication between patients and providers”. The authors also went 
on to state PROMs “have the potential to be as valuable to the clinical encounter 
as a stethoscope is to the physical examination”. However, the large-scale use of 
PROMs data requires both local infrastructure and local hospital Trust support. 
This can be costly and complex. To calculate a score for SAQ data I developed a 
spreadsheet in Microsoft Excel which used multiple columns and formulas. This 
could be built into hospital Trust Electronic Patient Record (EPR) systems. 
However, the SAQ is just one of many PROMs used and is specific to ischaemic 
heart disease. My Trust also treats patients with heart failure, valve disease, lung 
cancer, cystic fibrosis, congenital heart disease and those with arrhythmias 
needing pacemakers. Each population have different needs and utilise different 
PROMs. Building automatic systems to record PROMs for each disease 
population is possible but would require a commitment from the executive team, 
a dedicated development team including education and Information Technology 
and sufficient long- term funding.  
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Patients need to understand the potential of PROMs and perhaps local patient 
groups may help in this endeavour.  
7.5 An Opportunity for Improved Care 
This thesis could be said to reflect the famous quote from Dr William Osler to 
“Listen to your patient” “He’s telling you the diagnosis” (127). Osler was a pioneer, 
one of the first physicians to take his students out of the lecture theatre onto 
wards to meet patients. The NHS needs new pioneers. Healthcare is perhaps a 
misnomer as the NHS is predominately concerned with disease management and 
this is a costly business. In 2018 the healthcare expenditure was £214.4 billion, or 
£3,227 per person (128). That equates to 10% of this country’s gross domestic 
product. Total healthcare spending has doubled in the period 1997 to 2018.  
There have been great strides in incorporating routine collection of PROMs data 
in some surgical procedures such as hip and knee replacement.  However, this 
data is summative and can be used to compare results between trusts. A 
formative use of PROMs could inform both the patient and physician and aid 
decision making that benefits the patients’ QoL.  
7.6 Key Conclusions 
My work in chapter 6 comparing a short version of the SAQ containing just seven 
questions showed a very close relationship between the SAQ-7 and full SAQ 
summary score. It is possible to shorten a well-established and commonly used 
PROM. Although calculating the summary score involves several stages, this 
could be incorporated into an EPR system and used routinely. A summary score 
is easier to interpret than 5 individual domain scores, making sequential scores 
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easy to present in a graph for example. This information could then be seen by 
both clinicians and patients at each consultation or on ward rounds.  
This would be a small but important way to begin the process of changing the 
culture of PROMs in the UK. It would create the environment to incorporate both 
the clinicians’ expertise and patients’ QoL derived from a PROM. Ultimately, 
physicians need to embrace the potential of PROMs and, as Griggs et al state 
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Appendix i Example of EQ-5D 
 
Domain Level Tick if ‘Yes’ 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I have extreme problems in walking about  
   
Self-care 
I have no problems washing or dressing myself  
I have some problems washing or dressing myself  
I have extreme problems in washing or dressing myself  
   
Usual activities 
I have no problems with doing my usual activities  
I have some problems with doing my usual activities  
I have extreme problems doing my usual activities  
   
Pain Discomfort 
I have no pain or discomfort  
I have some pain or discomfort  
I have extreme pain or discomfort  
   
Anxiety 
Depression 
I am not anxious or depressed  
I have some anxiety or depression  
I have extreme anxiety or depression  
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Appendix ii Example of SAQ 
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